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Summary of findings {#CD012021-sec1-0001}
===================

Summary of findings for the main comparisonCurrent OST versus no OST for people who inject drugs**Current OST versus no OSTPatient or population**: people who inject drugs **Settings**: outpatient **Intervention**: current OST versus no OST**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Assumed riskCorresponding riskNo OSTCurrent OSTHCV incidence adjusted analyses** number of HCV seroconversion Follow‐up: mean 440.5 person‐years------**RR 0.50**\
(0.40 to 0.63)6361 (12 studies)⊕⊕⊝⊝ **Low**^a,b^\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI**: confidence interval; **OST**: opioid substitution therapy; **RR**: risk ratio.GRADE Working Group grades of evidence **High quality**: we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate quality**: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low quality**: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low quality**: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect[^2]

[Table 2](#CD012021-tbl-0002){ref-type="table"}Summary of findings 2High NSP coverage versus no/low NSP coverage for people who inject drugs**High NSP coverage versus no/low NSP coveragePatient or population**: people who inject drugs **Settings**: outpatients **Intervention**: high NSP coverage versus no/low NSP coverage**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Assumed riskCorresponding riskNo/low NSP coverageHigh NSP coverageHCV incidence adjusted analyses** number of HCV seroconversion Follow‐up: mean 269 person‐years------**RR: 0.79** (0.39 to 1.61)3530 (5 studies)⊕⊝⊝⊝ **Very low**^a,b^\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI**: confidence interval; **NSP**: needle syringe programmes; **RR**: risk ratio.GRADE Working Group grades of evidence **High quality**: we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate quality**: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low quality**: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low quality**: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.[^3]

[Table 3](#CD012021-tbl-0003){ref-type="table"}Summary of findings 3Combined OST and high NSP versus no OST and low/no NSP for people who inject drugs**Combined OST and highNSP versus no OST and low/no NSPPatient or population**: people who inject drugs **Settings**: outpatients **Intervention**: Combined OST and high/low NSP versus no OST and low/no NSP**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (studies)Quality of the evidence (GRADE)Assumed riskCorresponding riskNo OST and low/no NSPCombined OST and high NSPHCV incidence adjusted analyses** number of HCV seroconversions Follow‐up: mean 356 person‐years------**RR: 0.26** (0.07 to 0.89)3241 (3 studies)⊕⊕⊕⊝\
Low^a,b^\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI**: Confidence interval; **NSP**: needle syringe programmes; **OST**: opioid substitution therapy; **RR**: Risk ratio.GRADE Working Group grades of evidence **High quality**: we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate quality**: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low quality**: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low quality**: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.[^4]

Background {#CD012021-sec1-0002}
==========

Description of the condition {#CD012021-sec2-0001}
----------------------------

The number of people exposed to hepatitis C continues to increase globally, with an estimated 114.9 million people living with antibodies to hepatitis C ([@CD012021-bbs2-0149]), 3 to 4 million people newly infected each year and 350,000 deaths occurring annually ([@CD012021-bbs2-0164]; [@CD012021-bbs2-0166]). There were an estimated 35 million people living with human immunodeficiency virus (HIV) in 2014. Emerging evidence suggests that HIV transmission has declined since 2001 and more people are receiving treatment ([@CD012021-bbs2-0176]). Co‐infection with hepatitis C (HCV) among people living with HIV is a major global public health concern, with an estimated 4 million co‐infected people ([@CD012021-bbs2-0167]). Among people who inject drugs (PWID), sharing needle/syringes is the main risk factor for infection with HIV and HCV. Additional risks for HCV acquisition in this population include sharing drug preparation containers, filters, rinse water and backloading (a method of sharing drugs by transferring them from the needle of one syringe into the barrel of another) ([@CD012021-bbs2-0169]; [@CD012021-bbs2-0173]).

Description of the intervention {#CD012021-sec2-0002}
-------------------------------

NSPs are often a first point of contact with health services for PWID. They provide support to minimise drug and sexual risk‐related harms, including the provision of clean needles/syringes and condoms so as to prevent bloodborne virus transmission, bacterial infections and other adverse health outcomes. By maximising the amount of clean injecting equipment in circulation, it is possible to minimise the time that contaminated equipment remains in use and the proportion of unsafe injections ([@CD012021-bbs2-0142]; [@CD012021-bbs2-0159]). NSPs operate through a range of modalities including via fixed sites, outreach, peer PWID networks, vending machines and pharmacies. Engaging in behaviours that are socially stigmatised and illegal, PWID often have high rates of unemployment, homelessness and incarceration. NSPs also provide access to longer‐term support by referring clients to medical, drug treatment or social support services.

Drug treatment for opioid addiction and dependence also encompasses a range of strategies to manage injecting drug use and reduce associated harms, including medication‐assisted treatment (MAT) such as opioid substitution therapy (OST), MAT plus psychosocial approaches, and residential rehabilitation. The most commonly prescribed forms of OST are the opioid agonist treatments methadone maintenance therapy (MMT) and the partial agonist buprenorphine maintenance treatment (BMT). Buprenorphine plus the antagonist naloxone (licensed as \'Subuxone\') is also increasingly popular. OST is prescribed to dependent users to diminish the use and effects of illicitly acquired opioids. It is usually taken orally and therefore reduces the frequency of injection and unsafe injecting practices ([@CD012021-bbs2-0174]). As a treatment for opioid dependence, OST has been shown to increase health and social functioning, decrease crime and reduce the frequency of injection and unsafe injecting practices ([@CD012021-bbs2-0150]; [@CD012021-bbs2-0179]). Evidence suggests that OST is most effective when it is continuous and provided at adequate doses ([@CD012021-bbs2-0140]; [@CD012021-bbs2-0146]).

International evidence supports the use of combination interventions to prevent and treat HIV in PWID, with the provision of NSP, OST, and HIV antiretroviral treatment as the key interventions ([@CD012021-bbs2-0144]; [@CD012021-bbs2-0180]). There is good evidence that NSP and OST reduce injecting risk behaviours and increasing evidence showing an impact on HIV incidence ([@CD012021-bbs2-0141]; [@CD012021-bbs2-0160]). However, evidence of their impact on HCV incidence among PWID, in combination or alone, is limited ([@CD012021-bbs2-0147]; [@CD012021-bbs2-0148]; [@CD012021-bbs2-0150]; [@CD012021-bbs2-0158]; [@CD012021-bbs2-0165]; [@CD012021-bbs2-0175]; [@CD012021-bbs2-0027]).

How the intervention might work {#CD012021-sec2-0003}
-------------------------------

Two recent systematic reviews of 12 observational studies estimated that NSPs reduce HIV transmission among PWID by 48% (95% confidence interval (CI) 3% to 72%), with strong evidence that OST reduces HIV transmission by 54% (95% CI 33% to 68%) ([@CD012021-bbs2-0141]; [@CD012021-bbs2-0160]). However, none of the evidence was based on randomised controlled trials and either relied on cohort studies or cross‐sectional studies that measured OST or NSP exposure and HIV incident infections. Previous reviews synthesising evidence of the efficacy of NSPs have focused on HIV as the main outcome ([@CD012021-bbs2-0148]; [@CD012021-bbs2-0174]; [@CD012021-bbs2-0182]), thus failing to include all the available evidence on HCV ([@CD012021-bbs2-0165]).

A recent analysis of pooled data (N = 919) in a single country examined the effect of NSP coverage on HCV incidence, defining coverage in terms of the proportion of injections covered by a sterile syringe. This analysis suggested that high coverage of NSP (\'100% NSP\', i.e. obtaining at least one sterile syringes per injection) or OST (defined as receiving OST or not, either currently or within the previous 6 months) can each reduce the risk of HCV acquisition by 50%; and in combination by 80% ([@CD012021-bbs2-0175]). However, due to a small number of incident HCV cases (n = 40), the efficacy estimate for 100% or more NSP among those not on OST was weak (95% CI 0.22 to 1.12), and there was insufficient power to investigate the existence of a dose‐response relationship. Another systematic review examined evidence from observational studies on the impact of a range of risk reduction interventions on HCV acquisition, including behavioural interventions, NSP, and OST ([@CD012021-bbs2-0154]). This study measured the effect of NSP use, defined inconsistently due to limited available evidence, as any attendance at NSP or attendance at one point in time and showed increased risk of seroconversion among NSP attenders. Limitations of the studies included in this review were: substantial heterogeneity and lack of clarity and consistency in the measurement of NSP use across studies.

A recent review on the effect of OST use on HIV transmission identified many more studies than earlier Cochrane Reviews ([@CD012021-bbs2-0160]). Similarly, we suspected that not all evidence on the effect of NSP on HCV transmission had been identified, so extending previous reviews would strengthen the evidence base as well as provide a more refined measure of NSP coverage that accounts for frequency of attendance and degree to which NSPs meet individuals\' requirements for sterile needle/syringes.

Why it is important to do this review {#CD012021-sec2-0004}
-------------------------------------

Evidence of the effect of NSP with and without OST on HCV incidence is inconclusive ([@CD012021-bbs2-0165]). Previous reviews have failed to define the frequency of use of the intervention and/or the coverage of the intervention (defined as the quantity of needles/syringes received per injection) ([@CD012021-bbs2-0154]), and a previous pooled analysis had an insufficient sample size to accurately measure the effect ([@CD012021-bbs2-0175]). This review is needed in order to estimate the effect of NSPs using a consistent definition of coverage and examining impact with and without OST on HCV incidence, in order to inform harm reduction policies aimed at reducing the burden of HCV.

Objectives {#CD012021-sec1-0003}
==========

To assess the effects of needle syringe programmes and opioid substitution therapy, alone or in combination, for preventing acquisition of HCV in people who inject drugs.

We were specifically concerned with the following research questions.

How effective is OST alone for reducing HCV incidence in PWID?How effective are needle syringe programmes (NSP) with and without OST for reducing HCV incidence in PWID?How does the effect of NSP and OST vary according to duration of treatment (i.e. for NSPs weekly attendance versus monthly)?How does the effect of NSP vary according to the type of service (fixed site versus mobile; high coverage versus low coverage)?How does the effect of OST vary according to the dosage of OST, type of substitution used and adherence to treatment?

Methods {#CD012021-sec1-0004}
=======

Criteria for considering studies for this review {#CD012021-sec2-0005}
------------------------------------------------

### Types of studies {#CD012021-sec3-0001}

We included randomised controlled trials (RCTs), prospective and retrospective cohort studies and case‐control studies. We also followed up and included prospective studies examining HCV incidence in PWID that may have collected data regarding NSPs and OST without reporting the data in the published study, or which may have reported data as part of an adjusted analysis. For these studies, we sought unpublished data relating to the impact of NSP/OST on HCV transmission via contact with study authors. We included studies only when authors provided these data.

We included cross‐sectional surveys if they included a serological measure of recent infection (e.g. through positive ribonucleic acid (RNA) results on anti‐body negative samples). We excluded cross‐sectional studies (including serial cross‐sectional studies) reporting HCV prevalence alone. We excluded studies relying on self‐reported data for the outcome.

### Types of participants {#CD012021-sec3-0002}

People who inject drugs (opioids and or stimulants). We excluded studies enrolling participants undergoing opportunistic HCV testing (outside of the study setting) and those relating to people who inject drugs in the prison setting, since addiction services and treatment provision in this setting differ significantly from community and healthcare settings.

### Types of interventions {#CD012021-sec3-0003}

#### Experimental interventions {#CD012021-sec4-0001}

OSTNSPNSP plus OST

Studies could be based in a drug treatment facility or in the wider community, at a fixed site or mobile unit.

Exposure to OST was defined as continuous or interrupted treatment, current, recent (previous six months or duration of HCV observation period) or any past treatment with methadone or buprenorphine.

Exposure to NSP was defined as the proportion of injections covered by a clean needle/syringe or attendance at an NSP. Where it was not possible to estimate the proportion of injection covered by a clean needle/syringe, we defined exposure accounting for frequency of injection and the degree to which the NSP meets the individual\'s requirement for needles/syringes.

#### Control intervention {#CD012021-sec4-0002}

No OSTLow coverage NSP or no NSP

#### Types of comparisons {#CD012021-sec4-0003}

OST versus no OSTHigh NSP coverage with no OST versus low coverage NSPLow NSP coverage with no OST versus no NSPCombined high/low NSP coverage with OST versus no OST and low/no coverage NSP

### Types of outcome measures {#CD012021-sec3-0004}

#### Primary outcomes {#CD012021-sec4-0004}

Our review focused on one primary outcome, HCV incidence, and no other secondary outcomes. We excluded studies that did not report on HCV incidence since they would have addressed questions outside the main review question. Incidence of HCV infection in PWID was measured via repeat testing such as detection of HCV RNA positive among HCV antibody negative results or antibody avidity. We also included studies if they reported a minimum of two HCV seroconversions (HCV antibody negative to HCV antibody positive) in participants from tests conducted at different time points.

Search methods for identification of studies {#CD012021-sec2-0006}
--------------------------------------------

Methods to be used in this systematic review in relation to the search strategies and approaches to data synthesis follow methods applied in a similar review to assess the impact of OST on HIV incidence ([@CD012021-bbs2-0160]).

We identified papers in four ways. Firstly, we conducted two primary searches of the literature based on key search terms identified in reviews of the effect of OST and NSP on the risk of HIV and HCV among PWID ([@CD012021-bbs2-0160]; [@CD012021-bbs2-0165]). The purpose of the two searches were to identify studies that measured the impact of NSP/OST on HCV incidence (see [Appendix 1](#CD012021-sec2-0016){ref-type="app"}) and to identify longitudinal studies that measured HCV incidence and reported the impact of NSP/OST as part of an adjusted analysis (see [Appendix 2](#CD012021-sec2-0017){ref-type="app"}). The Cochrane Drugs and Alcohol Group Trials Search Co‐ordinator reviewed the search strategy and conducted the search.

### Electronic searches {#CD012021-sec3-0005}

We searched for relevant studies in the following sources.

The Cochrane Drugs and Alcohol Group Specialised Register of Trials (searched 16 November 2015).The Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 11).The Cochrane Database of Systematic Reviews (CDSR) (Cochrane Library, 2015, issue 11).The Database of Abstracts of Reviews of Effects (DARE)(Cochrane Library, 2015, issue 11).The Health Technology Assessment Database (HTA) (Cochrane Library, 2015, issue 11).The NHS Economic Evaluation Database (NHSEED) (Cochrane Library, 2015, issue 11).MEDLINE (Ovid) (1966 to 16 November 2015).Embase ([embase.com](embase.com)) (1974 to 16 November 2015).The Database of Abstracts of Reviews of Effects (DARE) (Cochrane Library, searched 16 November 2015).Global Health (Ovid) (1974 to 16 November 2015).CINAHL (EBSCOhost) (1982 to 16 November 2015).Web of Science (1991 to 16 November 2015).PsycINFO (Ovid) (1985 to 16 November 2015).

We searched for ongoing clinical trials and unpublished trials via searches of the following websites.

ClinicalTrials.gov ([www.clinicaltrials.gov](www.clinicaltrials.gov)).World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) ([apps.who.int/trialsearch/](apps.who.int/trialsearch/)).

This review fully incorporates the results of searches conducted up to November 2015. We identified a further four reports of studies in a search update conducted in March 2017. We have added those studies to [Studies awaiting classification](#CD012021-bbs1-0003){ref-type="ref-list"} and will incorporate them into the review at the next update.

### Searching other resources {#CD012021-sec3-0006}

We searched the publications of key international agencies including the European Monitoring Centre on Drugs and Drug Addiction, the European Centre for Disease Control, the National Institute on Drug Abuse, the US Institute of Medicine, the United Nations Office on Drugs and Crime Prevention and the World Health Organization. We handsearched the reference lists of relevant articles to identify additional relevant studies and contacted experts in the field to identify ongoing research. We also searched conference abstracts including the International Harm Reduction Conference, International HIV/AIDS Society and the European Association for the Study of the Liver conference. Finally we contacted principal investigators and authors of prospective studies that had examined HCV incidence in PWID but had not reported on the intervention exposure to see whether these data were available from unpublished sources.

There were no language or date restrictions, and we included peer reviewed and non‐peer reviewed papers.

Data collection and analysis {#CD012021-sec2-0007}
----------------------------

### Selection of studies {#CD012021-sec3-0007}

Two reviewers (LP, SM) independently screened all titles and abstracts, resolving disagreements following discussion. Two reviewers (LP, SM) independently screened full‐text copies of relevant articles to determine whether they met eligibility criteria for direct inclusion or for contact of study authors. We resolved disagreements by discussion or, where disagreements persisted, with adjudication by a third author (JR) to enable a consensus.

We had full‐text papers in languages other than English translated by individuals fluent in those languages. Where there were multiple publications from the same study, or the same city or region, we selected all published papers and extracted data from the study with the greatest number of outcome events (i.e. HCV seroconversions).

### Data extraction and management {#CD012021-sec3-0008}

One author (LP) extracted data using a data extraction form, which two review authors had pre‐piloted to determine suitability for capturing study data and assessing quality. A second author (JR) checked all data to assess the accuracy of data extraction. Data extracted included:

lead author;review title or unique identifier and date;eligibility for inclusion;reasons for exclusion;study aim(s);study design (included sampling methods, participant and attrition rate);study location;study setting;proportion of participants who injected opioids;proportion of participants who injected stimulants;definition of exposure (recency of injecting);intervention (NSP provision; number of needles distributed; frequency of injection; frequency of attendance; methadone maintenance therapy or buprenorphine maintenance treatment; delivery (e.g. continuous versus interrupted treatment); duration; dose);additional interventions or incentives provided alongside NSP/OST;participants (number in each intervention group; age, sex and ethnicity);duration of follow‐up in each treatment arm;outcome measure (HCV seroconversion) overall and by NSP and OST exposure;unadjusted and adjusted effect size: incidence rate ratio (IRR); odds ratio (OR); risk ratio (RR)hazard ratio (HR) and precision (i.e. 95% confidence interval (CI));confounding factors used to adjust effect estimates including high‐risk behaviours (injecting risk behaviours, frequency of injection, homelessness, experience of prison, duration of injection, or age, poly drug use);background prevalence of HCV in the population;any other comments.

### Assessment of risk of bias in included studies {#CD012021-sec3-0009}

We would have performed the \'Risk of bias\' assessment for RCTs using the criteria in the *Cochrane Handbook for Systematic Reviews of Interventions* ([@CD012021-bbs2-0155]). The recommended approach is a two‐part tool, addressing seven specific domains, namely sequence generation and allocation concealment (selection bias), blinding of participants and providers (performance bias), blinding of outcome assessor (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias) and other sources of bias. The first part of the tool involves describing what was reported to have happened in the study. The second part of the tool involves assigning a judgment relating to the risk of bias for that entry, in terms of low, high or unclear risk. To make these judgments we would have used the criteria indicated by [@CD012021-bbs2-0155]*,* adapted to the addiction field. See [Appendix 3](#CD012021-sec2-0018){ref-type="app"} for details. We would have assessed the risk of bias for unpublished estimates by referring to the study methods in the corresponding published paper.

We assessed the risk of bias in non‐randomised studies using a pilot version of a tool in development by the Methods Groups of the Cochrane Collaboration ([@CD012021-bbs2-0172]). This was undertaken as part of the formal piloting of the tool, in collaboration with its developers. The seven‐domain tool is an extension of the existing tool for assessing risk of bias in randomised trials ([@CD012021-bbs2-0155]).

Three domains concern the pre‐intervention phase or intervention phase.

Baseline confounding. In assessing bias due to confounding we considered there to be two critically important confounders: duration of injecting or age; and frequency of injecting.Selection of participants into the study.Measurement of the intervention.

Four domains relate to the post intervention phase.

Departures from intended interventions (performance bias).Missing data (attrition bias).Measurement of outcomes or interventions (detection bias).Selection of the reported results (outcome reporting bias).

Finally, we gave an overall risk of bias judgment at the study level for each relevant outcome (see [Appendix 4](#CD012021-sec2-0019){ref-type="app"}).

Since we were piloting a new \'Risk of bias\' tool, four contributors initially applied it independently to a sample of four studies. We discussed and compared assessments to ensure consistent interpretation of domains. Two people independently assessed the remaining studies in the review and compared results. We resolved disagreements by discussion.

### Measures of treatment effect {#CD012021-sec3-0010}

When trials reported only effect estimates, we directly extracted unadjusted and adjusted estimates reported as ORs, risk ratios (RRs), IRRs or HRs with 95% CIs. When studies provided only incidence data, we estimated rate ratios and 95% CIs based on the person‐years of observation. We extracted effect estimates reported as ORs and took them as an approximation of the RR, even though the incidence of HCV in included studies was variable (mean 18.7/100 person‐years, range 0.09 to 42). In order to account for this, we explored the impact of removing ORs on our overall intervention effect in sensitivity analyses([@CD012021-bbs2-0160]; [@CD012021-bbs2-0184]).

### Dealing with missing data {#CD012021-sec3-0011}

We contacted study authors if studies provided data regarding use of NSP or the impact of drug treatment on HCV transmission but insufficient detail regarding the precise form of treatment provided. We also contacted study authors if papers reported HCV incidence data but no data regarding drug treatment or NSP. If we could not obtain missing data, we excluded the studies from the review.

### Assessment of heterogeneity {#CD012021-sec3-0012}

We assessed heterogeneity via inspection of the forest plot and by a Chi^2^ test to demonstrate whether the observed differences in results were compatible with chance alone. We calculated tThe I^2^ statistic was calculated to examine the percentage of variability due to heterogeneity rather than to sampling error. We explored heterogeneity through sensitivity and subgroup analysis.

### Assessment of reporting biases {#CD012021-sec3-0013}

We used funnel plots (plots of the effect estimate from each study against the sample size or effect standard error) to assess the potential for bias related to the size of the trials, which could indicate possible publication bias. We inspected funnel plot symmetry when there were at least 10 studies included in the meta‐analysis.

### Data synthesis {#CD012021-sec3-0014}

We used a random‐effects model for all analyses, allowing for heterogeneity between studies and converting all effect estimates into RRs. We pooled adjusted and unadjusted effect estimates in separate meta‐analyses. We used Review Manager 5 (RevMan 5) for statistical analyses ([@CD012021-bbs2-0170]). We pooled data across different observational study designs and assessed the potential association between study design and effect size, stratifying by study design as well as in meta‐regression analyses.

### Subgroup analysis and investigation of heterogeneity {#CD012021-sec3-0015}

We examined heterogeneity with the I^2^ and Tau^2^ statistic and explored reasons for heterogeneity using univariable random‐effects meta‐regression to evaluate the impact of the following covariates: geographical region of study; recruitment setting (community‐based or treatment); percentage of female participants; main drug injected; type of NSP; frequency of injecting; dose, duration and adherence to NSP/OST (i.e. continuous or interrupted treatment); and study design. There was insufficient information to assess the impact of adherence to NSP/OST (i.e. continuous or interrupted treatment).

### Sensitivity analysis {#CD012021-sec3-0016}

We excluded studies that we assessed as being at critical risk of bias. We also used sensitivity analysis to determine to what extent the overall intervention effect changed when we excluded studies: at severe or unclear risk of bias; that did not adjust for confounders; from unpublished datasets; and that used odds ratios as effect measures and were cross‐sectional in design.

#### Summary of findings table {#CD012021-sec4-0005}

We assessed the overall quality of the evidence for the primary outcome using the GRADE system for assessing the quality of evidence ([@CD012021-bbs2-0151]; [@CD012021-bbs2-0152]; [@CD012021-bbs2-0153]; [@CD012021-bbs2-0171]). GRADE takes into account issues not only related to internal validity but also to external validity, such as directness of results. The \'Summary of findings\' tables present the main findings of the review in a transparent and simple tabular format. In particular, they provide key information concerning the quality of evidence, the magnitude of effect of the interventions examined and the sum of available data on the main outcomes.

The GRADE system uses the following criteria for assigning grades of evidence.

*High*: we are very confident that the true effect lies close to that of the estimate of the effect.*Moderate*: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.*Low*: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.*Very low*: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Grading is decreased for the following reasons.

Serious (−1) or very serious (−2) study limitation for risk of bias.Serious (−1) or very serious (−2) inconsistency between study results.Some (−1) or major (−2) uncertainty about directness (the correspondence between the population, the intervention, or the outcomes measured in the studies actually found and those under consideration in our systematic review).Serious (−1) or very serious (−2) imprecision of the pooled estimate(−1).Publication bias strongly suspected (−1).

Grading is increased for observational studies for the following reasons.

Strong evidence of association ‐ significant relative risk of more than 2.0 (or less than 0.5) based on consistent evidence from two or more observational studies, with no plausible confounders (+1).Very strong evidence of association ‐ significant relative risk of more than 5.0 (or less than 0.2) based on direct evidence with no major threats to validity (+2).Evidence of a dose response gradient (+1).All plausible confounders would have reduced the effect (+1).

Results {#CD012021-sec1-0005}
=======

Description of studies {#CD012021-sec2-0008}
----------------------

### Results of the search {#CD012021-sec3-0017}

We identified 6720 unique records from database searching and from reference lists of included studies and relevant reviews. We excluded 6576 on the basis of title and abstract and retrieved 144 full‐text articles for more detailed evaluation. We excluded 103 of these (referring to 101 studies) after reading the full text because they did not meet the inclusion criteria; we characterised 6 studies as awaiting classification since they were written in Chinese or German, and we were not able to translate.

We finally included 28 studies (31 references): 21 published and 7 unpublished reports that satisfied all criteria required for inclusion in the review. See [Figure 1](#CD012021-fig-0001){ref-type="fig"}.Figure 1Study flow diagram.

Twenty‐one papers directly included measures of the impact of exposure to either OST or NSP on HCV acquisition. In addition, we identified 11 eligible prospective studies that measured HCV incidence and contacted authors of these articles. Of these, we obtained unpublished data from six cohort studies in Montreal, Canada ([@CD012021-bbs2-0002]); Baltimore, USA ([@CD012021-bbs2-0013]), San Francisco, USA ([@CD012021-bbs2-0015]); London, UK ([@CD012021-bbs2-0010]); Melbourne, Australia ([@CD012021-bbs2-0001]); and Sydney, Australia ([@CD012021-bbs2-0012]); plus one cross‐sectional survey ([@CD012021-bbs2-0009]).

### Included studies {#CD012021-sec3-0018}

See [Characteristics of included studies](#CD012021-sec2-0022){ref-type="sec"}.

In total we included 21 published studies ([@CD012021-bbs2-0003]; [@CD012021-bbs2-0004]; [@CD012021-bbs2-0005]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0008]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0014], [@CD012021-bbs2-0016] ; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0019]; [@CD012021-bbs2-0020]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0022]; [@CD012021-bbs2-0023]; [@CD012021-bbs2-0024]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0026]; [@CD012021-bbs2-0027]; [@CD012021-bbs2-0028]), plus 7 unpublished studies ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0002]; [@CD012021-bbs2-0009], [@CD012021-bbs2-0010]; [@CD012021-bbs2-0012][@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]), comprising 1817 HCV incident infections and 8806.95 person‐years of follow‐up. HCV incidence in the 28 studies ranged from 0.09 and 42 cases per 100 person‐years.

#### Design {#CD012021-sec4-0006}

We did not identify any randomised controlled trials. We included 2 case‐control studies ([@CD012021-bbs2-0005], [@CD012021-bbs2-0018]), 3 cross‐sectional studies ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0016]), 20 prospective cohort studies ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0002]; [@CD012021-bbs2-0003]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0015]; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0020]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0022]; [@CD012021-bbs2-0023]; [@CD012021-bbs2-0024]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0027]; [@CD012021-bbs2-0028]); 2 retrospective cohort studies ([@CD012021-bbs2-0004]; [@CD012021-bbs2-0026]); and 1 serial cross‐sectional survey ([@CD012021-bbs2-0019]).

#### Duration of trials {#CD012021-sec4-0007}

For cohort studies the duration of follow‐up ranged between 1 and 22 years. Included studies were published between 1995 and 2014.

#### Participants and setting {#CD012021-sec4-0008}

Twenty‐five studies reported participants\' sex, and the mean proportion of female participants was 32% (range 2.8% to 55.9%). Across 14 studies, on average 40.7% (range 9.2% to 69.2%) of participants had experience of recent or past homelessness, and 35% (range 18.2% to 90%) had experience of prison (12 studies). The mean reported use of stimulants was 32.7% (range 0% to 75%, 19 studies) and a mean of 50.5% (range 18.2% to 100%) reported heroin use (13 studies). Across 14 studies a mean of 50.6% of participants reported injecting daily (range 18.2% to 84%).

Most study participants were currently injecting at the time of recruitment, with eligibility criteria for study participation stated as: injection in the previous four weeks ([@CD012021-bbs2-0003]; [@CD012021-bbs2-0008]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0015]; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0022]; [@CD012021-bbs2-0024]; [@CD012021-bbs2-0025]), in the previous 3 months to 6 months ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0002]; [@CD012021-bbs2-0005]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0019]; [@CD012021-bbs2-0020]; [@CD012021-bbs2-0023]), or in the previous 6 months to 12 months ([@CD012021-bbs2-0006]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0028]). A few studies included PWID who had injected at any time in the past ([@CD012021-bbs2-0011], [@CD012021-bbs2-0013]; [@CD012021-bbs2-0027]), or they reported no information on recency of injection ([@CD012021-bbs2-0004]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0026]).

Eight studies took place in the USA; five each in the UK, Canada and Australia; and one each in the Netherlands, France, Italy, Spain and China.

#### Study size and method of recruitment {#CD012021-sec4-0009}

Sample size ranged from 46 and 2788. The method of recruitment primarily involved street outreach, in 13 studies ([@CD012021-bbs2-0003]; [@CD012021-bbs2-0004]; [@CD012021-bbs2-0005]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0015]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0019]; [@CD012021-bbs2-0022]; [@CD012021-bbs2-0024]; [@CD012021-bbs2-0026]; [@CD012021-bbs2-0027]); respondent‐driven sampling, in 3 studies ([@CD012021-bbs2-0007]; [@CD012021-bbs2-0008]; [@CD012021-bbs2-0009]); and service attenders (both low‐threshold community services and drug treatment), in 12 studies ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0002]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0020]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0023]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0028]). Most studies drew on a combination of recruitment methods.

#### Types of interventions {#CD012021-sec4-0010}

Twenty‐one of the included studies assessed the impact of OST ([@CD012021-bbs2-0003]; [@CD012021-bbs2-0004]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0020]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0022]; [@CD012021-bbs2-0024]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0026]; [@CD012021-bbs2-0027]; [@CD012021-bbs2-0028]), including seven unpublished estimates ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0002]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]).

Current use of OST was defined as: reporting use of prescribed methadone or buprenorphine within the previous six months (yes or no) ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0028]); use for more than six months ([@CD012021-bbs2-0010]), use of methadone or buprenorphine at the time of survey ([@CD012021-bbs2-0003]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0021]), or continuous use of methadone throughout follow‐up period ([@CD012021-bbs2-0004]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0022]). [@CD012021-bbs2-0027] defined continuous use as daily use of methadone (any dosage) in the previous six months, while [@CD012021-bbs2-0001] defined it as in the previous one month. [@CD012021-bbs2-0024] used a three‐month time frame to measure use of OST (methadone or buprenorphine).

Seventeen studies assessed the impact of NSP ([@CD012021-bbs2-0005]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0019]; [@CD012021-bbs2-0023]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0027]; [@CD012021-bbs2-0028]), including five unpublished sources ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]).

[@CD012021-bbs2-0002] defined high NSP coverage as obtaining 100% of needles/syringes from a safe source (receiving one clean needle for every injection), [@CD012021-bbs2-0008][@CD012021-bbs2-0009]and [@CD012021-bbs2-0027] defined it as reporting ≥100% of injections using clean needles/syringes (receiving one or more clean needle for every injection), and [@CD012021-bbs2-0016] defined it as reporting ≥200% of injections with clean syringes (receiving more than two clean needles for every injection). Other measures of high coverage were defined as regular attendance at least once per week at an NSP in [@CD012021-bbs2-0017] or obtaining most needles/syringes from an NSP in the last six months ([@CD012021-bbs2-0006]).

Low‐level NSP coverage was defined as ever having used an NSP ([@CD012021-bbs2-0005]), using NSPs in the previous one to six months ([@CD012021-bbs2-0007]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]; [@CD012021-bbs2-0019]; [@CD012021-bbs2-0023]; [@CD012021-bbs2-0028]), or having less than 100% of injections covered by a clean needle/syringe in the last six months ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0027]).

Four studies assessed the impact of combined NSP with OST ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0027]), including one unpublished data source ([@CD012021-bbs2-0002]). Studies defined combined use of NSP plus OST in two ways: high NSP coverage plus current use of OST ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0027]), and OST use plus low NSP coverage ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0027]). One study looked at the impact of uptake of injecting paraphernalia (defined as spoons and filters) alone, with needles/syringes and in combination with OST ([@CD012021-bbs2-0016]).

### Excluded studies {#CD012021-sec3-0019}

See [Characteristics of excluded studies](#CD012021-sec2-0023){ref-type="sec"}.

We excluded 101 studies (104 articles). Grounds for exclusion were: no outcome of interest assessed (43 studies); no intervention of interest (32 studies); no comparison of interest (all participants on OST, 9 studies); no outcome and no intervention of interest (11 studies); no outcome and no comparison of interest (4 studies); and editorial or overview (2 studies).

Risk of bias in included studies {#CD012021-sec2-0009}
--------------------------------

### Bias due to baseline confounding {#CD012021-sec3-0020}

We judged 12 studies to be at moderate risk of bias due to confounding because they adjusted for critical confounders (duration of injecting or age, and frequency of injecting) and used a suitable analysis method (e.g. adjusted for time‐varying confounding if appropriate) ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0008]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]; [@CD012021-bbs2-0022]; [@CD012021-bbs2-0024]; [@CD012021-bbs2-0028]). We judged 12 to be at serious risk because confounding was insufficiently addressed in the analyses ([@CD012021-bbs2-0003]; [@CD012021-bbs2-0005]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0019]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0023]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0027]). The four studies we assessed as being at critical risk did not make any adjustment for confounding ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0004]; [@CD012021-bbs2-0020]; [@CD012021-bbs2-0026]).

### Bias in the selection of participants into the study {#CD012021-sec3-0021}

We deemed five studies to be at moderate risk of bias because start of follow‐up and start of intervention coincided for all or most subjects ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0022]; [@CD012021-bbs2-0024]). We judged three studies to be at critical risk of bias because selection into the study was strongly related to intervention and outcome ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0020]). We considered the remaining studies to be at serious risk of selection bias, largely because participants may have already been exposed to the intervention prior to the start of the study. For two studies ([@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]), we did not have enough information to make a judgment.

### Bias in measurement of the intervention {#CD012021-sec3-0022}

We judged five studies to be at low risk of bias because intervention status was well defined and based solely on information collected at the time of intervention ([@CD012021-bbs2-0004]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0022]; [@CD012021-bbs2-0024]; [@CD012021-bbs2-0025]). We deemed seven studies to be at moderate risk because some aspects of the assignments of intervention status were determined retrospectively ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0027]; [@CD012021-bbs2-0028]). We considered [@CD012021-bbs2-0010] to be at critical risk of bias because there was considerable risk of misclassification of intervention status. We judged the remaining studies to be at serious risk of selection bias mainly because intervention status was not well defined. For two studies ([@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]), we did not have enough information to make a judgment.

### Blinding {#CD012021-sec3-0023}

**Departures from intended interventions**: none of the studies provided information about co‐interventions received by participants or changes in treatment, so we coded departures from intended interventions as \'no information\' for all studies.

**Measurement of outcomes**: we deemed all but one study to be at low risk of bias in relation to measurement of the outcome since HCV seroconversion was laboratory‐confirmed, and testing was carried out at pre‐defined time points, with no apparent differences between intervention groups. In[@CD012021-bbs2-0004], the risk was serious because there may have been differential testing (for participants not on methadone, the need for HCV testing was determined according to the clinician\'s judgment).

### Incomplete outcome data {#CD012021-sec3-0024}

Six studies were at a low risk of bias because data were reasonably complete ([@CD012021-bbs2-0005]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0008]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0022]), and two studies were at moderate risk of bias because there were no substantial differences in the proportions of missing data or in reasons for missing data across intervention groups ([@CD012021-bbs2-0023]; [@CD012021-bbs2-0024]). The eight studies at serious risk ([@CD012021-bbs2-0003]; [@CD012021-bbs2-0004]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0020]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0027]), and the five at critical risk ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0019]; [@CD012021-bbs2-0026]), had substantial differences in either the proportions of missing participants or the reasons for missing data across interventions, and investigators did not adjust for these differences in the analyses. Seven studies provided insufficient information about missing data or the potential for data to be missing ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]; [@CD012021-bbs2-0028]).

### Selective reporting {#CD012021-sec3-0025}

We judged all studies to be at low risk for selective reporting as the measure of the outcome of interest was clearly defined and internally consistent. For one study ([@CD012021-bbs2-0001]), there was insufficient information for assessing reporting bias.

#### Overall risk of bias {#CD012021-sec4-0011}

We judged only 2 studies to be at moderate overall risk of bias ([@CD012021-bbs2-0022]; [@CD012021-bbs2-0024]), while 17 were at serious overall risk ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0003]; [@CD012021-bbs2-0005]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0008]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0023]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0028]), and 7 were at critical risk ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0004]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0019]; [@CD012021-bbs2-0020]; [@CD012021-bbs2-0026]). For two studies, we did not have enough information to make a judgment ([@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]). This is summarised in [Table 16](#CD012021-tbl-0016){ref-type="table"}.Table 1Risk of bias of included studies**StudyConfoundingSelection biasMeasurement of interventionsDepartures from intended interventionsMissing dataMeasurement of outcomesSelection of reported resultOverall risk of bias**[@CD012021-bbs2-0001]CriticalCriticalSeriousNo infoCriticalLowNo infoCritical[@CD012021-bbs2-0002]ModerateSeriousModerateNo infoNo infoLowLowSerious[@CD012021-bbs2-0003]SeriousSeriousSeriousNo infoSeriousLowLowSerious[@CD012021-bbs2-0004]CriticalSeriousLowNo infoSeriousSeriousLowCritical[@CD012021-bbs2-0005]SeriousSeriousSeriousNo infoLowLowLowSerious[@CD012021-bbs2-0006]ModerateSeriousLowNo infoLowLowLowSerious[@CD012021-bbs2-0007]SeriousSeriousModerateNo infoNo infoLowLowSerious[@CD012021-bbs2-0008]ModerateModerateSeriousNo infoLowLowLowSerious[@CD012021-bbs2-0009]ModerateModerateSeriousNo infoNo infoLowLowSerious[@CD012021-bbs2-0010]ModerateCriticalCriticalNo infoCriticalLowLowCritical[@CD012021-bbs2-0011]ModerateSeriousSeriousNo infoSeriousLowLowSerious[@CD012021-bbs2-0012]ModerateSeriousSeriousNo infoNo infoLowLowSerious[@CD012021-bbs2-0013]ModerateNo infoNo infoNo infoNo infoLowLowNo info[@CD012021-bbs2-0014]SeriousSeriousModerateNo infoLowLowLowSerious[@CD012021-bbs2-0015]ModerateNo infoNo infoNo infoNo infoLowLowNo info[@CD012021-bbs2-0016]SeriousSeriousModerateNo infoSeriousLowLowSerious[@CD012021-bbs2-0017]SeriousModerateSeriousNo infoSeriousLowLowSerious[@CD012021-bbs2-0018]SeriousLowSeriousNo infoCriticalLowLowCritical[@CD012021-bbs2-0019]SeriousSeriousSeriousNo infoCriticalLowLowCritical[@CD012021-bbs2-0020]CriticalCriticalSeriousNo infoSeriousLowLowCritical[@CD012021-bbs2-0021]SeriousSeriousModerateNo infoLowLowLowSerious[@CD012021-bbs2-0022]ModerateModerateLowNo infoLowLowLowModerate[@CD012021-bbs2-0023]SeriousSeriousSeriousNo infoModerateLowLowSerious[@CD012021-bbs2-0024]ModerateModerateLowNo infoModerateLowLowModerate[@CD012021-bbs2-0025]SeriousSeriousLowNo infoSeriousLowLowSerious[@CD012021-bbs2-0026]CriticalSeriousSeriousNo infoCriticalLowLowCritical[@CD012021-bbs2-0027]SeriousSeriousModerateNo infoSeriousLowLowSerious[@CD012021-bbs2-0028]ModerateSeriousModerateNo infoNo infoLowLowSerious

Effects of interventions {#CD012021-sec2-0010}
------------------------

See: [Table 1](#CD012021-tbl-0001){ref-type="table"}; [Table 2](#CD012021-tbl-0002){ref-type="table"}; [Table 3](#CD012021-tbl-0003){ref-type="table"}

### 1. Current use of OST versus no current OST {#CD012021-sec3-0026}

Of the 20 studies that assessed the impact of OST on HCV incidence, we pooled data from 17 studies that measured current OST ([@CD012021-bbs2-0003]; [@CD012021-bbs2-0004]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0021]; [@CD012021-bbs2-0022]; [@CD012021-bbs2-0024]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0027]; [@CD012021-bbs2-0028]), including five unpublished estimates ([@CD012021-bbs2-0001]; [@CD012021-bbs2-0002]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0012]).

Fourteen of the included studies were longitudinal studies, one used a case‐control study design ([@CD012021-bbs2-0018]), and two were cross‐sectional surveys ([@CD012021-bbs2-0009]; [@CD012021-bbs2-0016]). A total of 1148 HCV incident cases were included over 6553.1 person‐years of follow‐up.

The primary analyses were focused on twelve studies presenting adjusted estimates. These analyses included the following effect measures: hazard ratios in six studies ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0011]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0024]; [@CD012021-bbs2-0028]), odds ratios in five studies ([@CD012021-bbs2-0010]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0018]; [@CD012021-bbs2-0022]), and incident rate ratio in two studies ([@CD012021-bbs2-0003]; [@CD012021-bbs2-0013]).

Adjusted estimates controlled for potential confounding effects of the following factors: duration and frequency of injection ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0010]); area of residence, homelessness, sharing injecting equipment or needles ([@CD012021-bbs2-0003]); sex, geographical region, use of condoms, injection of cocaine, duration of injection, sharing injecting equipment ([@CD012021-bbs2-0011]); duration of injection, frequency of injection and age of whole cohort ([@CD012021-bbs2-0013]); unstable housing, cocaine, heroin or methamphetamine injection, cohort of recruitment, year of recruitment, follow‐up time ([@CD012021-bbs2-0014]); survey year, homelessness, stimulant injection, duration of injection ([@CD012021-bbs2-0016]); sex, age, duration of drug use, injection of cocaine ([@CD012021-bbs2-0018]); age, duration of injection, sex, ethnicity, homelessness or prison in the last 3 months ([@CD012021-bbs2-0024]); sex, ethnicity, age, frequency of injecting and sharing needles/syringes ([@CD012021-bbs2-0028]); and injected at follow‐up, pooled money to buy drugs, injected with used needles and backloading (removing the plunger from a syringe and filling it with drug solution from another needle/syringe) ([@CD012021-bbs2-0022]).

Random‐effects meta‐analysis of multivariable estimates showed that opioid substitution therapy was associated with a 50% reduction in the risk of HCV infection (RR 0.50 95% CI 0.40 to 0.63) with little heterogeneity between 12 studies involving 6361 participants (I^2^ = 0%, P = 0.89, Tau^2^ = 0.00; [Analysis 1.1](#CD012021-fig-00101){ref-type="fig"}; [Figure 2](#CD012021-fig-0002){ref-type="fig"}).Figure 2Forest plot of comparison: 1 Current OST versus no OST, outcome: 1.1 HCV incidence adjusted analyses by region.

#### Sensitivity analysis {#CD012021-sec4-0012}

The intervention effect strengthened when we excluded estimates from four unpublished data sources ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0010]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]): RR 0.42 (95% CI 0.31 to0.58; [Analysis 2.1](#CD012021-fig-00201){ref-type="fig"}; I^2^ = 0%, Tau^2^ = 0.00, 8 studies, N = 5235).

This effect was maintained when the analysis was limited to excluding [@CD012021-bbs2-0010] and [@CD012021-bbs2-0018], judged to be at critical risk of bias, and [@CD012021-bbs2-0013], which reported insufficient information to give an overall risk of bias assessment (RR 0.51, 95% CI 0.40 to 0.64; [Analysis 3.1](#CD012021-fig-00301){ref-type="fig"} I^2^ = 0%, Tau^2^ = 0.00). The intervention effect was also unchanged when the analysis excluded [@CD012021-bbs2-0016] and [@CD012021-bbs2-0018], two cross‐sectional studies that reported baseline measures of effect only (RR 0.51, 95% CI 0.40 to 0.65; [Analysis 4.1](#CD012021-fig-00401){ref-type="fig"}; I^2^ = 0.0%, Tau^2^ = 0.00, 10 studies, N = 3367).

Random‐effects meta‐analysis of 16 studies that presented unadjusted estimates shows that current OST was associated with a 43% reduction in the risk of HCV acquisition (RR 0.57, 95% CI 0.45 to 0.73; [Analysis 5.1](#CD012021-fig-00501){ref-type="fig"}; 16 studies, N = 10,647), with only moderate evidence of heterogeneity between studies (I^2^ = 32.4%, P = 0.09, Tau^2^ = 0.08).

#### Meta‐regression {#CD012021-sec4-0013}

Based on univariable meta‐regression of unadjusted estimates, we found no evidence that effectiveness varied by other covariates including geographical location ([Analysis 1.1](#CD012021-fig-00101){ref-type="fig"}) or study design ([Analysis 1.2](#CD012021-fig-00102){ref-type="fig"}). We did find evidence of differential impact in the proportion of female participants in the sample. With each 10% increase of female participants in sample, the effect of intervention exposure was reduced (ratio of rate ratios = 1.59, 95% CI 1.13 to 2.29; [Table 17](#CD012021-tbl-0017){ref-type="table"}).Table 2Univariable meta‐regression analysis for studies measuring impact of current use of OST on HCV incidence**VariableStudiesUnivariable rate ratio (95% CI)Ratio of rate ratios**\
**(95% CI)P valueTau^2^Geographic region**Europe80.51 (0.37‐0.70)1.0 (ref)------Australia50.55 (0.28‐1.11)1.12 (0.52‐2.41)------North America60.69 (0.44‐1.08)1.42 (0.73‐2.78)0.530.10**Site of recruitment**Service attenders120.67 (0.49‐0.92)1.0 (ref)------Community70.49 (0.33‐0.73)0.73 (0.42‐1.27)0.2560.06**Study design**Cross‐sectional40.51 (0.31‐0.85)1.0------Prospective cohort150.58 (0.43‐0.77)1.12 (0.48‐2.61)0.7840.10Females17---**1.59 (1.13‐2.29)**0.010.04Prison experience11---1.057 (0.61‐1.79)0.8210.43Experience of homelessness12---1.08 (0.83‐1.40)0.5210.23Injection of stimulants12---0.89 (0.65‐1.22)0.3730.17Daily injection7---0.88 (0.64‐1.22)0.3730.17[^5]

#### History of OST {#CD012021-sec4-0014}

Three studies published unadjusted estimates of lifetime use of OST versus never using OST, comprising 115 HCV cases over 511.6 person‐years from three prospective cohorts ([@CD012021-bbs2-0020]; [@CD012021-bbs2-0025]; [@CD012021-bbs2-0026]). One study did not define the time frame, so we coded it as lifetime experience of OST ([@CD012021-bbs2-0025]).

Three studies published unadjusted estimates of interrupted OST use versus no interruption of use ([@CD012021-bbs2-0004]; [@CD012021-bbs2-0014]; [@CD012021-bbs2-0022]). Two of these studies were prospective cohorts and one retrospective; they included a total of 200 HCV cases over 2273.8 person‐years. Interrupted OST use was defined either as use of MMT at baseline but not at follow‐up ([@CD012021-bbs2-0014]), or leaving MMT at least once during follow‐up ([@CD012021-bbs2-0004]; [@CD012021-bbs2-0022]).

One prospective cohort study comprising 149 HCV cases over 680 person‐years examined OST for detoxification ([@CD012021-bbs2-0024]), and two studies measured high (60 mg or more) or low dosage (less than 60 mg) methadone in the last 6 months ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0027]). Both these studies were prospective cohorts and included 148 HCV cases over 598.6 person‐years.

Random‐effects meta‐analysis showed a very weak protective effect for lifetime (RR 0.81, 95% CI 0.52 to 1.27, I^2^ = 0%, Tau^2^ = 0.00, 3 studies, N = 385) or interrupted use of OST (RR 0.80, 95% CI 0.57 to 1.10, I^2^ = 86.1%, Tau^2^ = 0.05, 3 studies, N = 1157). The one study measuring the impact of OST used for detoxification was not associated with reduced HCV risk acquisition (RR 1.45, 95% CI 0.79 to 2.66, Tau^2^ = 0.00, N = 552). In the two studies that categorised OST dosage and HCV acquisition, we found a moderate association for those exposed to high dosage OST (RR 0.52, 95% CI 0.29 to 0.94, I^2^ = 27.2%, Tau^2^ = 0.05, N = 453) and a very weak association for those exposed to low dosage OST (RR 0.85, 95% CI 0.44 to 1.65; [Analysis 1.3](#CD012021-fig-00103){ref-type="fig"}; I^2^ = 61.2%, Tau^2^ = 0.14, N = 453).

#### Publication bias {#CD012021-sec4-0015}

A funnel plot of 13 estimates (12 studies) suggested no evidence of publication bias in studies of current OST exposure ([Figure 3](#CD012021-fig-0003){ref-type="fig"}).Figure 3Funnel plot of comparison: 1 Current OST versus no OST, outcome: 1.1 HCV incidence adjusted analyses by region.

### 2. Needle syringe programmes versus lower or no NSP coverage {#CD012021-sec3-0027}

Of the 15 studies that reported measures of NSP exposure and HCV incidence, comparison groups consisted of NSP non‐attendance ([@CD012021-bbs2-0005]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]; [@CD012021-bbs2-0017]; [@CD012021-bbs2-0019]; [@CD012021-bbs2-0023]; [@CD012021-bbs2-0027]), lower coverage of injections covered by a clean needle/syringe ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0027]), and non‐attendance at NSP and not using a safe source for obtaining needles/syringes ([@CD012021-bbs2-0002]).

#### 2.1 High coverage versus non‐attendance or lower coverage {#CD012021-sec4-0016}

Five studies reported adjusted measures of high NSP coverage and HCV incidence ([@CD012021-bbs2-0006]; [@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0017]), including one unpublished dataset ([@CD012021-bbs2-0002]). Three were prospective cohorts ([@CD012021-bbs2-0002], [@CD012021-bbs2-0006], [@CD012021-bbs2-0017]), and two were cross‐sectional surveys ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]), comprising 407 HCV cases over 1644 person‐years. Effect measures used in these studies included: hazard ratios in two studies ([@CD012021-bbs2-0002], [@CD012021-bbs2-0017]), odds ratios in two studies ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]), and risk ratio in one study ([@CD012021-bbs2-0006]).

Random‐effects meta‐analysis showed weak evidence that high coverage NSP was not associated with reduced risk of HCV infection (RR 0.79, 95% CI 0.39 to 1.61) derived from 5 studies with 3530 participants and high heterogeneity between studies (I^2^ =77%, P = 0.002, Tau^2^=0.44; [Figure 4](#CD012021-fig-0004){ref-type="fig"}; [Analysis 6.1](#CD012021-fig-00601){ref-type="fig"}).Figure 4Forest plot of comparison: 2 High NSP coverage versus no/low NSP coverage, outcome: 2.1 HCV incidence adjusted analyses by region.

##### Sensitivity analyses {#CD012021-sec5-0001}

Evidence of any intervention effect became weaker after excluding the unpublished dataset of [@CD012021-bbs2-0002] (RR 0.77, 95% CI 0.28 to 2.13; [Analysis 7.1](#CD012021-fig-00701){ref-type="fig"}; Tau^2^ = 0.81, 4 studies, N = 3245). We did not rate any studies as being at critical risk of bias. The intervention effect disappeared when we excluded [@CD012021-bbs2-0008] and [@CD012021-bbs2-0016], two cross‐sectional studies (RR 1.25, 95% CI 0.63 to 2.46; [Analysis 8.1](#CD012021-fig-00801){ref-type="fig"}; I^2^ = 77.0%, Tau^2^ = 0.27, 3 studies, N = 627).

Random‐effects meta‐analysis of seven studies that presented unadjusted estimates show that the weak intervention effect was unchanged (RR 0.78, 95% CI 0.39 to 1.55; [Analysis 9.1](#CD012021-fig-00901){ref-type="fig"}; I^2^ = 79%, Tau^2^ = 0.72).

##### Meta‐regression {#CD012021-sec5-0002}

Based on univariable meta‐regression analyses, we found evidence that the effectiveness of high NSP coverage varied according to geographical region. High NSP coverage was associated with a 76% reduction in HCV acquisition risk (RR 0.24, 95% CI 0.09 to 0.62), with less heterogeneity between two European studies in 2903 participants (I^2^ = 0%, P = 0.66). There was no evidence of an intervention effect from studies in North America (RR 1.25, 95% CI 0.63 to 2.46; [Analysis 6.1](#CD012021-fig-00601){ref-type="fig"}; I^2^ = 77%, 3 studies, N = 627; [Figure 4](#CD012021-fig-0004){ref-type="fig"}). There was some evidence of a differential impact in the meta‐regression analysis (ratio of rate ratios 3.73, 95% CI 0.95 to 14.7, P = 0.057; [Table 18](#CD012021-tbl-0018){ref-type="table"}). Although univariable meta‐regression analysis suggested some association between high coverage of NSP and study design (ratio of rate ratios 3.5, 95% CI 0.78 to 15.8, P = 0.087), this was reduced when adjusted by geographical region (ratio of rate ratios 1.7, 95% CI 0.18 to 16.9, P = 0.58), suggesting any association is confounded by region ([Analysis 6.2](#CD012021-fig-00602){ref-type="fig"}; [Table 18](#CD012021-tbl-0018){ref-type="table"}).Table 3Univariable meta‐regression analysis for studies measuring impact of high NSP coverage on HCV incidence**VariableStudiesUnivariable rate ratio (95%CI)Ratio of rate ratios (95%CI)P valueTau^2^Geographic region**Europe50.44 (0.24‐0.80)1.0 (Ref)------North America31.58 (0.57‐4.42)**3.73 (0.95‐14.7)**0.0570.41**Recruitment site**Service attenders30.67 (0.28‐1.59)1.0 (Ref)------Community50.82 (0.29‐2.32)0.76(0.12‐4.88)0.740.89**Study design**Cross‐sectional survey30.34 (0.16‐0.75)1.0 (Ref)------Prospective cohort41.26 (0.55‐2.93)3.53 (0.78‐15.86)0.0870.48Females7---2.97(0.38‐23.1)0.240.87Prison experience3---NA------Experience of homelessness6---1.01 (0.38‐2.67)0.9761.53Injection of stimulants7---1.08 (0.47‐2.51)0.8271.15Daily injection5---3.66 (0.22‐61.3)0.2391.15[^6]

#### 2.2 Low‐level coverage of NSP versus no NSP coverage {#CD012021-sec4-0017}

Six studies involving 2763 participants reported adjusted measures of low‐level NSP coverage and HCV incidence ([@CD012021-bbs2-0005]; [@CD012021-bbs2-0006]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]). Random‐effects meta‐analysis showed no evidence of an intervention effect of low NSP coverage on HCV risk acquisition, with moderate levels of heterogeneity (RR 1.43, 95% CI 0.82 to 2.49; [Analysis 10.1](#CD012021-fig-01001){ref-type="fig"}; I^2^ = 69.1%, Tau^2^ = 0.272).

##### Sensitivity analysis {#CD012021-sec5-0003}

Ten studies reported unadjusted measures of low‐level NSP coverage and HCV incidence. Eight were prospective cohorts ([@CD012021-bbs2-0006]; [@CD012021-bbs2-0007]; [@CD012021-bbs2-0012]; [@CD012021-bbs2-0013]; [@CD012021-bbs2-0015]; [@CD012021-bbs2-0023]; [@CD012021-bbs2-0027]; [@CD012021-bbs2-0028]), and one was a case‐control study ([@CD012021-bbs2-0005]). We excluded another prospective cohort study since it did not report 95% confidence intervals around the effect estimate, nor the number of new HCV cases in intervention and comparison groups required to estimate it ([@CD012021-bbs2-0019]). A total of 531 cases were included in the analyses over 1617 person‐years. Random‐effects meta‐analysis showed no evidence of an intervention effect for low NSP coverage on HCV risk acquisition, with moderate levels of heterogeneity (RR 1.41 95% CI 0.95 to 2.09; [Analysis 11.1](#CD012021-fig-01101){ref-type="fig"}; I^2^ = 62.3%, Tau^2^ = 0.19, 9 studies, N = 3242).

### 3. Combined needle syringe programmes plus opioid substitution therapy versus low or no NSP coverage and no OST {#CD012021-sec3-0028}

Four studies reported combined exposure to both NSPs and OST ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0027]) including one unpublished dataset ([@CD012021-bbs2-0002]). The primary analyses focused on three studies presenting adjusted estimates ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0027]). A total of 511 HCV incident cases were included in the analysis examining high NSP coverage, and 437 cases for low NSP coverage. Only one study reported the number of person‐years ([@CD012021-bbs2-0027]).

Random‐effects meta‐analysis showed that combined use of OST plus high coverage of NSP was associated with a 76% risk reduction in HCV acquisition (RR 0.26, 95% CI 0.07 to 0.89; [Analysis 12.1](#CD012021-fig-01201){ref-type="fig"}; I^2^ = 80%, Tau^2^ = 0.94; 3 studies, N = 3241; [Figure 5](#CD012021-fig-0005){ref-type="fig"}). The effect of exposure to OST and low coverage of NSP was weaker (RR 0.87, 95% CI 0.44 to 1.68; [Analysis 12.1](#CD012021-fig-01201){ref-type="fig"}; I^2^ = 36.0%, Tau^2^ = 0.09; 2 studies, N = 2956 participants; [Figure 5](#CD012021-fig-0005){ref-type="fig"}).Figure 5Forest plot of comparison: 4 Combined OST and high/low NSP versus no OST and low/no NSP, outcome: 4.1 HCV incidence adjusted analyses.

#### Sensitivity analysis {#CD012021-sec4-0018}

Four studies reported unadjusted estimates of combined exposure to both NSPs and OST ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]; [@CD012021-bbs2-0027]) including one unpublished dataset ([@CD012021-bbs2-0002]). Two were cross‐sectional surveys ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0016]), and two were prospective cohorts ([@CD012021-bbs2-0002]; [@CD012021-bbs2-0027]). The analysis examining high NSP coverage included a total of 518 HCV incident cases, and the analysis for low NSP coverage, 449 cases. Random‐effects meta‐analysis showed that combined use of OST plus high coverage of NSP was associated with a 71% risk reduction in HCV acquisition (RR 0.29, 95% CI 0.13 to 0.65, I^2^ = 64.4%, Tau^2^ = 0.07, 4 studies, N = 3356). The effect of exposure to OST and low coverage of NSP was weaker (RR 0.76, 95% CI 0.44 to 1.33; [Analysis 12.2](#CD012021-fig-01202){ref-type="fig"}; I^2^ = 29.6%, Tau^2^ = 0.4, 3 studies, N = 2956).

Discussion {#CD012021-sec1-0006}
==========

Summary of main results {#CD012021-sec2-0011}
-----------------------

### Opioid substitution treatment (OST) {#CD012021-sec3-0029}

Primary meta‐analysis of 12 observational studies adjusting for key confounders and enrolling 6361 anti‐HCV negative participants showed that current use of opioid substitution therapy reduced the risk of HCV acquisition by 50% (95% CI 37% to 60%) compared to no current OST use. The intervention effect is strong, but the evidence is considered as low quality because it was derived from observational studies with serious risk of bias. Nonetheless, the findings were robust to sensitivity analyses excluding studies judged to be at critical risk of bias; studies drawing on unpublished data; case‐control and cross‐sectional studies only reporting baseline data; and studies reporting only unadjusted estimates. There was also no evidence of publication bias.

Meta‐regression analysis suggested evidence of a differential impact of OST by the proportion of female participants in the sample. With each 10% increase in female participants, the effect of intervention exposure was reduced by 59%. None of the included studies reported uptake of OST by sex to understand whether individual‐level analyses supported this evidence of a differential intervention effect. Other epidemiological evidence suggests that women are at increased risk of acquiring hepatitis C compared to men ([@CD012021-bbs2-0145]; [@CD012021-bbs2-0157]; [@CD012021-bbs2-0163]; [@CD012021-bbs2-0109]). This increased risk has been linked to having a sexual partner who also injects, being initiated into injection by a sexual partner being injected by others or consistently injecting after other people with used needles/syringes ([@CD012021-bbs2-0143]; [@CD012021-bbs2-0157]). Our findings suggest that women may have poorer access to OST than men, and this is supported by recent review work that suggests services do not take into account gender‐specific needs and are often tailored towards men ([@CD012021-bbs2-0157]).

Only a few studies reported other types of exposure to OST: three studies reported past exposure to OST; three reported interrupted OST use; one study measured OST use for detoxification; and two studies measured high dosage (more than 60 mg) or low dosage (1 to 59 mg) of methadone for daily use. Among these exposures, only high dosage of OST was associated with a reduction in risk of HCV acquisition.

### Needle and syringe programmes (NSP) {#CD012021-sec3-0030}

Meta‐analysis of five observational studies pooling adjusted estimates from 3530 anti‐HCV negative participants show low‐quality evidence that high NSP exposure does not reduce the risk of HCV acquisition. Selected sensitivity analyses increased the uncertainty around the intervention effect. However,meta‐regression showed a strong association between intervention effect and region. After removing studies from North America, heterogeneity was reduced, and high NSP coverage in Europe was associated with a 76% (95% CI 38% to 91%) reduction in HCV acquisition risk (RR 0.24, 95% CI 0.09 to 0.62).

### Combined NSP and OST {#CD012021-sec3-0031}

Primary meta‐analysis of three studies involving 3241 anti‐HCV negative participants and adjusting for confounders suggested a strong intervention effect for combined high coverage of NSP and OST, reducing the risk of HCV acquisition by 74% (95% CI 11% to 93%) compared to no OST and low/no coverage with NSP. The evidence is considered low quality because it was derived from observational studies with serious risk of bias, and the few studies identified precluded sensitivity analyses. Evidence for the combination of low coverage of NSP and OST was weaker. There were fewer studies with information on both OST and NSP coverage, and the studies represented a subset of people on OST (i.e. participants who continue to inject drugs while on OST), with those on low coverage NSP receiving an insufficient number of sterile syringes per average frequency of injecting.

Overall completeness and applicability of evidence {#CD012021-sec2-0012}
--------------------------------------------------

We found no historical RCT evidence that assessed the impact of NSP or OST on HCV transmission. There was a larger body of observational evidence that examined the effectiveness of NSPs and OST in reducing HCV acquisition among PWID -- but the evidence was concentrated in few geographical areas and regions. Most evidence came from North America and Western Europe. Only one study was identified from China ([@CD012021-bbs2-0020]), and we did not find any studies from Eastern Europe or Southeast Asia, where there are the largest populations of PWID and hence the highest burden of disease associated with bloodborne infections ([@CD012021-bbs2-0149]; [@CD012021-bbs2-0161]; [@CD012021-bbs2-0167]).

Quality of the evidence {#CD012021-sec2-0013}
-----------------------

We assessed many studies included in the review as being at severe risk of bias -- with only two being at moderate overall risk and seven at critical risk. Only a few studies reported the intervention effect of high NSP coverage adjusting for confounders (5/7), which limited the sensitivity analyses that we could conduct. The GRADE assessment criteria takes RCTs to be the gold standard study design, and observational studies are by default rated as low quality, so the assessment begins low, despite this being the only evidence available for examining this question. While certainty in the results may be undermined by the lack of experimental studies, the intervention effect estimates for current use of OST were consistent and robust across sensitivity analyses, and the size of effect is high. GRADE guidelines also state that judgments about the overall quality of evidence require information beyond the results of the review ([@CD012021-bbs2-0151]). Considering the wealth of supporting evidence showing the beneficial effects of OST in reducing injecting harms, HIV and bacterial infections, and in improving access to services, we are confident that the assessment is fair ([@CD012021-bbs2-0154]; [@CD012021-bbs2-0160]; [@CD012021-bbs2-0165]; [@CD012021-bbs2-0175]; [@CD012021-bbs2-0177]; [@CD012021-bbs2-0178]).

Potential biases in the review process {#CD012021-sec2-0014}
--------------------------------------

A potential bias in the review was the heterogeneity across the studies in the use of multiple effect measures. Effect measures were converted into risk ratios in the meta‐analysis, but this may have introduced bias into our findings since we had to assume that risk ratios approximated odds ratios, which may be inappropriate for some sites given the high incidence of HCV seroconversion. We removed cross‐sectional study designs that identified serological markers of incidence infection as part of our sensitivity analysis. Effect estimates remained the same for current use of OST versus no intervention, but not for high coverage of NSPs. Nonetheless, most studies recruited people who inject drugs currently or recently, which may not be representative of all PWID exposed to OST and may lead to an underestimation of the effect of OST on HCV transmission. For example, in the Amsterdam cohort, people who reported being on OST and having ceased injecting had a lower risk of HCV transmssion ([@CD012021-bbs2-0027]). Another potential bias is the use in three studies of HCV RNA testing for anti‐HCV negative samples to obtain an estimate of incidence ([@CD012021-bbs2-0008]; [@CD012021-bbs2-0009]; [@CD012021-bbs2-0016]). Potential limitations of this method include delayed or weak antibody response due to a compromised immune system and uncertainty around the incidence window period ([@CD012021-bbs2-0156]). All included studies estimating incidence from RNA samples used the same formula and comparable window periods. We didn\'t include any studies that used avidity testing, minimising any further misclassification of outcomes that that approach brings through the uncertainty in window periods.

Agreements and disagreements with other studies or reviews {#CD012021-sec2-0015}
----------------------------------------------------------

Our review corroborates and underpins an earlier review that showed consistent and large effects of NSP and OST on injecting risk behaviours associated with bloodborne virus transmission ([@CD012021-bbs2-0150]). Two recent reviews focused on the effectiveness of OST and NSPs in reducing HCV incidence. Our findings corroborate the most recent pooled analysis, which suggested that receiving OST and high coverage of NSP can each reduce HCV infection risk alone but have a greater effect in combination ([@CD012021-bbs2-0175]). The estimate for association between exposure to NSP and HCV incidence was weak in the pooled analysis and was focused on studies from the UK only. Findings from our subgroup analysis suggested a stronger effect of high NSP coverage in Europe. This finding builds directly on the [@CD012021-bbs2-0175] analysis through the addition to the meta‐analysis of the earlier [@CD012021-bbs2-0027] along with more recent studies and datasets ([@CD012021-bbs2-0009]), and it strengthens the efficacy estimate for Europe suggesting reduced risk of HCV acquisition (RR 0.24 95% CI 0.09 to 0.62). We found no effect of high NSP coverage when pooling estimates from North America and greater heterogeneity across the studies. This corroborates findings from another review that found increased risk of seroconversion associated with NSP attendance that relied on evidence predominantly from North America ([@CD012021-bbs2-0154]).

The lack of evidence for NSPs from studies in North America can be attributed to a mixture of confounding, differences in injecting patterns, potential selection bias and misclassification of exposure. People who attend NSPs regularly also report greater injecting risk behaviours, and any positive association between HCV transmission and NSP attendance disappears after adjustment for injecting risk. The effect of this residual confounding has been demonstrated in further analyses of a cohort of PWID in Vancouver, which demonstrated that higher HIV seroconversion rates observed among daily NSP attenders were associated with high‐risk behaviours of attenders (including regular cocaine injection, sex work involvement and homelessness) rather than use of the NSP ([@CD012021-bbs2-0183]). Likewise, a study in Seattle showed that people who were homeless or who injected with used needle/syringes were more likely to become new NSP users ([@CD012021-bbs2-0060]). The higher proportion of stimulant injecting in North America also means that the additional protective effect of OST is absent, which may contribute to the impact of NSP on HCV risk in European studies. Potential selection bias may occur since samples of cohort studies are to some degree self‐selected. Particularly when participants are lost to follow‐up over time, they may be inherently different in terms of demographic characteristics and risk behaviours that can influence the outcome. Misclassification of exposure may also occur since it is difficult to make a clear distinction between exposed and unexposed groups, and unexposed populations may have access to clean needles/syringes through other sources than NSPs. The European studies consistently used measures of NSP exposure through coverage of injections by clean needles/syringes, whereas the North American studies drew on varied definitions of NSP use that focused on frequency of attendance at NSPs. Comparability in measurement of intervention exposure is reflected in the higher heterogeneity observed among studies measuring exposure to NSP (I^2^ = 77%, P = 0.002) compared to OST exposure (I^2^ = 0%, P = 0.89). This is particularly relevant in relation to measures of intervention exposure that focus on frequency of attendance at an NSP rather than a measure of injections covered by clean needle/syringes, and further explains the lack of effect between high NSP coverage and HCV incidence observed in North America. It is also possible that the lack of effect of NSPs on HCV transmission observed in North America is due to less frequent use of NSPs. Previous evidence has shown that lack of federal funding for NSPs in the USA has resulted in lower coverage among PWID, and this has been associated with higher HIV incidence than in other countries with higher NSP coverage ([@CD012021-bbs2-0181]).

Findings also corroborate two recent systematic reviews that measured the impact of NSPs and OST on HIV transmission. These previous analyses of 12 observational studies estimated a moderate effect of NSPs on reducing HIV transmission by 48% (95% CI 3% to 72%) and strong evidence for OST reducing HIV transmission by 54% (95% CI 33% to 68%) ([@CD012021-bbs2-0141]; [@CD012021-bbs2-0160]).

A previous review of reviews from 2010 concluded that there was insufficient evidence to assess the effectiveness of NSPs in reducing HCV incidence. This \'meta\' review synthesised findings from four primary reviews, three of which focused primarily on HIV as an outcome, missing much of the relevant data, and the fourth predominantly relied on weaker study designs ([@CD012021-bbs2-0165]).

Authors\' conclusions {#CD012021-sec1-0007}
=====================

Opioid substitution treatment (OST) reduces the risk of HCV acquisition in PWID. The evidence for the effectiveness of high coverage needle syringe programmes (NSP) was more mixed -- with evidence from studies in Europe suggesting that NSP reduce HCV transmission, but not in the USA, probably due to misclassification of intervention exposure, selection bias of study participants and unmeasured bias. The intervention effect is strengthened with the combination of OST and high coverage NSP. The World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS, the United Nations Office on Drugs and Crime, the European Centre for Disease Prevention and Control, and the European Monitoring Centre for Drugs and Drug Addiction all recommend OST and NSPs as key interventions for preventing drug‐related harm, including HCV transmission. Yet OST is not widely implemented in many countries, prohibited in the Russian Federation and often restricted by age or duration of dependency prior to treatment entry ([@CD012021-bbs2-0162]).Our findings show the need to remove restrictions on the concurrent use of both NSP and OST to maximise reduction in HCV transmission. Distribution of needles/syringes through NSPs needs to be maintained alongside provision of OST. NSP and OST services need to recognise the role of gender and develop appropriate policies and practice to encourage women to use services addressing the specific injecting‐related risk behaviours they face and addressing other health and social welfare needs. We only identified three studies that examined effectiveness of interrupted use of OST, but effectiveness was reduced. Similarly, available evidence to examine differences in effect by dosage was limited.There is low‐quality evidence demonstrating the effectiveness of OST for reducing risk behaviour and transmission of HCV and HIV. However, there is a need to understand the role of duration of OST use in reducing the risk of both HIV and HCV. For NSPs, evidence needs to be strengthened. There is a need for more consistent measurement in the coverage of NSPs across epidemiological studies to obtain better effect estimates for NSPs as well as understanding how injection of stimulants or prescription opioids changes their effectiveness. There is a need for better studies on NSP impact in North America and for combining studies on OST and NSP implementation and roll‐out and effect on HCV transmission in general in low‐ and middle‐income countries. Given the body of observational evidence on effect of OST and NSP on reducing HIV, HCV incidence and other injecting related harms, it is not ethical to individually randomise exposure to OST or NSP, so future trial evidence can only be derived from cluster‐randomised controlled trials or stepped wedge design. Current guidance means that the quality of the evidence will typically be assessed as low.Research direction also needs to turn to implementation and understanding how NSPs and OST can be scaled up and delivered more effectively to better respond to the health needs of PWID, which requires observational study designs. We know that effectiveness of NSP varies by geographical location, but without the provision of counselling (psychosocial and voluntary counselling and testing for HIV and HCV), education and drug treatment services like opioid substitution therapy, NSPs are insufficient to reduce epidemics of HIV and HCV in PWID ([@CD012021-bbs2-0103]; [@CD012021-bbs2-0177]). More detailed assessments should examine service delivery and their cost‐effectiveness in order to ensure existing services are maintained and to promote the introduction and scale‐up of services in countries and settings with emerging or growing epidemics of injecting and opioid drug use. This line of research can shed light on the pathways between contextual factors and mechanisms of service delivery, and the extent to which these influence effectiveness across different outcomes. For example, HIV and HCV epidemics continue unchecked in Eastern Europe despite implemention of OST and NSP in some countries ([@CD012021-bbs2-0178]). Epidemics are growing in countries in sub‐Saharan Africa, including Tanzania and Kenya, where OST is currently being implemented, but there has been little formal evaluation of different models of delivery; specific economic, social and political contexts; and the impact of specific epidemiology of HIV and HCV. Further, we identified only one study conducted in a middle‐income country (China) and no studies in low‐income countries. There was insufficient evidence to examine differences in effectiveness by NSP modality or setting of OST. This reflects a lack of evaluation of provision of OST or NSP in other settings. Further research is needed to examine how the effect of NSP differs by service modality, including pharmacies, mobile clinics or outreach services. Similarly, research into the effectiveness of OST delivered in specialist services, community settings and prisons is needed.While evidence for the combined effect of OST and high NSP coverage is stronger, we only identified four studies, and only three of those adjusted for confounders. Further evidence is needed to understand how effectiveness may differ by modality, duration of OST as well as impact on other health outcomes associated with injecting drug use, including bacterial infections and mental health, among others. Given the low quality of evidence, there is a need to improve transparency and consistency in reporting of observational studies to facilitate systematic reviews of observational studies.

We thank Shruti Mehta, Thomas Kerr, Meghan Morris and Ali Judd for access to unpublished data and providing measures of association between the interventions and HCV risk acquisition that were used in the analysis. We thank Zuzana Mitrova for her support with the searches. We thank Julian Higgins for his advice on the use of the ACROBAT \'Risk of bias\' assessment tool and statistical advice on the options for pooling different observational study designs.
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**CENTRAL, DARE, NHSEED and HTA (Cochrane Library)**

MeSH descriptor: \[Needle‐Exchange Programs\] explode all treesMeSH descriptor: \[Community Pharmacy Services\] explode all trees((needle\* or syringe\* or inject\*) near/3 exchange):ti,ab,kw (Word variations have been searched)MeSH descriptor: \[Harm Reduction\] explode all trees(harm near/2 reduc\*):ti,ab,kw (Word variations have been searched)(needle\* or syringe\* or inject\*) near/3 (suppl\* or access\* or provision or provid\* or distribut\* or dispens\* or pack\*):ti,ab,kw (Word variations have been searched)(needle\* or syringe\* or inject\*) near/3 (program\* or service\* or center\* or centre\* or scheme\* or facility or facilities or area\* or pharmacy or pharmacies or unit or units or room\*):ti,ab,kw (Word variations have been searched)(needle\* or syringe\* or inject\* or slot or dispensing or vending) near/3 (machine\* or (peer next distrib\*)):ti,ab,kw (Word variations have been searched)\#1 or \#2 or \#3 or \#4 or \#5 or \#5 or \#6 or \#7 or \#8MeSH descriptor: \[Substance Abuse, Intravenous\] explode all trees((substance\* or drug\* or opiate\* or opioid\* or heroin\* or morphin\* or morfin\* or narcot\*) near/6 (use\* or abus\* or misuse\* or addict\* or depend\*)):ti,ab,kw (Word variations have been searched)(substance\* or drug) and (inject\* or intravenous):ti,ab,kw (Word variations have been searched)\#10 or \#11 or \#12MeSH descriptor: \[Opiate Substitution Treatment\] explode all treesMeSH descriptor: \[Methadone\] explode all treesMeSH descriptor: \[Buprenorphine\] explode all trees(substitut\* or maint\*) near/2 (treatment or therapy):ti,ab,kw (Word variations have been searched)(methadone or buprenorphine or subutex or suboxone):ti,ab,kw (Word variations have been searched)\#13 or \#14 or \#15 or \#16 or \#17 or \#18\#9 or \#19MeSH descriptor: \[Hepatitis C\] explode all trees(hepatitis next C) or (hep next C):ti,ab,kw (Word variations have been searched)HCV:ti,ab\#21 or \#22 or \#23\#13 and \#20 and \#24

**MEDLINE, PsycINFO and Global Health (Ovid)**

Needle‐Exchange Programs/Community pharmacy services/((needle\* or syringe\* or inject\*) adj3 exchange).ab,ti.Harm Reduction/(harm adj reduc\*).ab,ti.((needle\* or syringe\* or inject\*) adj3 (suppl\* or access\* or provision or provid\* or distribut\* or dispens\* or pack\*)).ab,ti.((needle\* or syringe\* or inject\*) adj3 (program\* or service\* or center\* or centre\* or scheme\* or facility or facilities or area\* or pharmacy or pharmacies or unit or units or room\*)).ab,ti.((needle\* or syringe\* or inject\* or slot or dispensing or vending) adj3 (machine\* or (peer adj distrib\*))).ab,ti.or/1‐8Substance Abuse, Intravenous/(substance\$ or drug\$).ab,ti.(abuse\$ or depend\$ or use\$ or misus\$ or addict\$).ab,ti.(inject\$ or intravenous).ab,ti.10 or (11 and 12) or (11 and 13)opiate substitution treatment/methadone/buprenorphine/(((substitut\* or maint\*) adj2 (treatment or therapy)) or methadone or buprenorphine or subutex or suboxone).ab,ti.or/15‐18exp Hepatitis C/(hepatitis‐c or or hep c or hcv).ab,ti.20 or 21(9 or 19) and 14 and 22

**EMBASE (embase.com)**

\'substance abuse\'/exp OR \'substance abuse\' OR ((substance\* OR drug\* OR opiate\* OR opioid\* OR heroin\* OR morphin\* OR morfin\* OR narcot\*) NEAR/6 (use\* OR abus\* OR misuse\* OR addict\* OR depend\*)):ab,ti OR ((substance\* OR drug\*) NEAR/6 (inject\* OR intravenous)):ab,ti AND (\'hepatitis c\'/exp OR \'hepatitis‐c\':ab,ti OR \'hep c\':ab,ti OR hcv:ab,ti) AND (\'preventive health service\'/exp OR ((needle\* OR syringe\* OR inject\*) NEAR/3 exchange):ab,ti OR \'harm reduction\'/exp OR (harm NEAR/2 reduc\*):ab,ti OR ((needle\* OR syringe\* OR inject\*) NEAR/3 (suppl\* OR access\* OR provision OR provid\* OR distribut\* OR dispens\* OR pack\*)):ab,ti OR ((needle\* OR syringe\* OR inject\*) NEAR/3 (program\* OR service\* OR center\* OR centre\* OR scheme\* OR facility OR facilities OR area\* OR pharmacy OR pharmacies OR unit OR units OR room\*)):ab,ti OR ((needle\* OR syringe\* OR inject\* OR slot OR dispensing OR vending) NEAR/3 (machine\* OR peer)):ab,ti OR \'opiate substitution treatment\'/exp OR \'methadone\'/exp OR methadone:ab,ti OR \'buprenorphine\'/exp OR \'buprenorphine\':ab,ti OR ((substitut\* OR maint\*) NEAR/2 (treatment OR therapy)):ab,ti OR subutex:ab,ti OR suboxone:ab,ti)

**CINAHL (EBSCO)**

(MH \"Needle Exchange Programs\")TI((needle\* OR syringe\*OR inject\*) N3 exchange) OR AB(needle\* OR syringe\* OR inject\*) N3 exchange)(MH \"Harm Reduction\")TI (harm N2 reduc\*) OR AB (harm N2 reduc\*)TI ((needle\* OR syringe\* OR inject\*) N3 (suppl\* OR access\* OR provision OR provid\* OR distribut\* OR dispens\* OR pack\*) ) OR AB ( TI(needle\* OR syringe\* OR inject\*) N3 (suppl\* OR access\* OR provision OR provid\* OR distribut\* OR dispens\* OR pack\*))TI ((needle\* OR syringe\* OR inject\*) N3 (program\* OR service\* OR center\* OR centre\* OR scheme\* OR facility OR facilities OR area\* OR pharmacy OR pharmacies OR unit OR units OR room\*)) OR AB ( (needle\* OR syringe\* OR inject\*) N3 (program\* OR service\* OR center\* OR centre\* OR scheme\* OR facility or facilities OR area\* OR pharmacy OR pharmacies OR unit OR units OR room\*))TI (((needle\* OR syringe\* OR inject\* OR slot OR dispensing OR vending) N3 (machine\*OR (peer N2 distrib\*)))) OR AB ( ((needle\* OR syringe\* OR inject\* OR slot OR dispensing OR vending) N3 (machine\* OR (peer N2 distrib\*))))S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7(MH \"Substance Abuse, Intravenous\")TI ((substance\* OR drug\* OR opiate\* OR opioid\* OR heroin\* OR morphin\* OR morfin\* OR narcot\*) N6 (use\* OR abus\* OR misuse\* OR addict\* OR depend\*))AB ((substance\* OR drug\* OR opiate\* OR opioid\* OR heroin\* OR morphin\* OR morfin\* OR narcot\*) N6 (use\* OR abus\* OR misuse\* OR addict\* ORdepend\*))TI (substance\* OR drug\*) AND TI (inject\* OR intravenous)AB(substance\* OR drug\* ) AND AB( inject\* OR intravenous)S9 OR S10 OR S11 OR S12 OR S13(MH \"Methadone\") OR (MH \"Buprenorphine\")TI (methadone or buprenorphine or subutex or suboxone) OR AB (methadone or buprenorphine or subutex or suboxone)TX (substitut\* or maint\*) N2 (treatment or therapy)S15 OR S16 OR S17(MH \"Hepatitis C+\")TI ( \"hepatitis‐c\" or \"hep c\" or hcv ) OR AB ( \"hepatitis‐c\" or \"hep c\" or hcv )S19 OR S20S8 OR S18S14 AND S21 AND S22

**Web of Science (THOMSON REUTERS)**

TOPIC: (((needle\* OR syringe\* OR inject\*) NEAR/3 exchange))TOPIC: (harm NEAR/2 reduc\*)TOPIC: (((needle\* OR syringe\* OR inject\*) NEAR/3 (suppl\* OR access\* OR provision OR provid\* OR distribut\* OR dispens\* OR pack\*)))TOPIC: ((needle\* or syringe\* or inject\*) near/3 (program\* or service\* or center\* or centre\* or scheme\* or facility or facilities or area\* or pharmacy or pharmacies or unit or units or room\*))TOPIC: ((needle\* or syringe\* or inject\* or slot or dispensing or vending) NEAR/3 (machine\* orpeer))\#5 OR \#4 OR \#3 OR \#2 OR \#1TOPIC: (((substance\* OR drug\* OR opiate\* OR opioid\* OR heroin\* OR morphin\* OR morfin\* OR narcot\*) NEAR/6 (use\* OR abus\* OR misuse\* OR addict\* OR depend\*)))TOPIC: ((substance\* or drug) and (inject\* or intravenous))\#8 OR \#7TOPIC: ((substitut\* or maint\*) near/2 (treatment or therapy))TOPIC: ((methadone or buprenorphine or subutex or suboxone))\#11 OR \#10TOPIC: (\"Hepatitis C\")TOPIC: (\"Hep C\")TOPIC: (HCV)\#15 OR \#14 OR \#13\#12 OR \#6\#17 AND \#16 AND \#9

Indexes=SCI‐EXPANDED, SSCI, A&HCI Timespan=All years

**MEDLINE, PsycINFO & Global Health (Ovid)**

Substance Abuse, Intravenous/(substance\$ or drug\$).ab,ti.(abuse\$ or depend\$ or use\$ or misus\$ or addict\$).ab,ti.(inject\$ or intravenous).ab,ti.1 or (2 and 3) or (2 and 4)exp Hepatitis C/(hepatitis‐c or hcv).ab,ti.(HCV adj2 seroconvers\$).ti,ab.(HCV adj2 transmission).ti,ab.or/6‐9exp Cohort Studies/exp Longitudinal Studies/(prospective or longitudinal or cohort).ti,ab.or/11‐135 and 10 and 14Animals/15 not 16

**Embase (embase.com)**

\'substance abuse\'/exp OR ((substance\* OR drug\* OR opiate\* OR opioid\* OR heroin\* OR morphin\* OR morfin\* OR narcot\*) NEAR/6 (use\* OR abus\* OR misuse\* OR addict\* OR depend\*)):ab,ti OR ((substance\* OR drug\*) NEAR/6 (inject\* OR intravenous)):ab,ti AND (\'hepatitis c\'/exp OR \'hepatitis‐c\':ab,ti OR \'hep c\':ab,ti ORhcv:ab,ti) AND (\'cohort analysis\'/exp OR \'longitudinal study\'/exp OR prospective:ab,ti OR longitudinal:ab,ti OR cohort:ab,ti)

**CINAHL (EBSCO)**

(MH \"Substance Abuse, Intravenous\")TI ((substance\* OR drug\* OR opiate\* OR opioid\* OR heroin\* OR morphin\* OR morfin\* OR narcot\*) N6 (use\* OR abus\* OR misuse\* OR addict\* OR depend\*))AB ((substance\* OR drug\* OR opiate\* OR opioid\* OR heroin\* OR morphin\* OR morfin\* OR narcot\*) N6 (use\* OR abus\* OR misuse\* OR addict\* OR depend\*))TI ( substance\* OR drug\* ) AND TI ( inject\* OR intravenous )AB( substance\* OR drug\* ) AND AB( inject\* OR intravenous )S1 OR S2 OR S3 OR S4 OR S5(MH \"Hepatitis C+\")TI ( \"hepatitis‐c\" or \"hep c\" or hcv ) OR AB ( \"hepatitis‐c\" or \"hep c\" or hcv )S7 OR S8(MH \"Prospective Studies+\")TI ( prospective or longitudinal or cohort ) OR AB ( prospective or longitudinal or cohort )S10 OR S11S6 AND S9 AND S12

**Web of Science (THOMSON REUTERS)**

TOPIC: (((substance\* OR drug\* OR opiate\* OR opioid\* OR heroin\* OR morphin\* OR morfin\* OR narcot\*) NEAR/6 (use\* OR abus\* OR misuse\* OR addict\* OR depend\*)))TOPIC: ((substance\* or drug) and (inject\* or intravenous))\#1 OR \#2TOPIC: (\"Hepatitis C\")TOPIC: (\"Hep C\")TOPIC: (HCV)\#4 OR \#5 OR \#6TOPIC: (prospective or longitudinal or cohort)\#3 AND \#7 AND \#8

Indexes=SCI‐EXPANDED, SSCI, A&HCI Timespan=All years

**ItemJudgmentDescription**1. Random sequence generation (selection bias)Low riskThe investigators describe a random component in the sequence generation process such as: random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation.High riskThe investigators describe a non‐random component in the sequence generation process such as: odd or even date of birth; date (or day) of admission; hospital or clinic record number; alternation; judgment of the clinician; results of a laboratory test or a series of tests; availability of the intervention.Unclear riskInsufficient information about the sequence generation process to permit judgment of low or high risk2. Allocation concealment (selection bias)Low riskInvestigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based, and pharmacy‐controlled, randomisation); sequentially‐numbered drug containers of identical appearance; sequentially‐numbered, opaque, sealed envelopes.High riskInvestigators enrolling participants could possibly foresee assignments because one of the following method was used: open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. if envelopes were unsealed or non­opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.Unclear riskInsufficient information to permit judgment of low or high risk. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgment.3. Blinding of participants and providers (performance bias)\
Objective outcomesLow riskNo blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding\
Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been brokenHigh riskNo blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding\
Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blindingUnclear riskInsufficient information to permit judgment of low or high risk4. Blinding of participants and providers (performance bias)\
Subjective outcomesLow riskBlinding of participants and providers ensured and unlikely that the blinding could have been brokenHigh riskNo blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding\
Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blindingUnclear riskInsufficient information to permit judgment of low or high risk5. Blinding of outcome assessor (detection bias)\
Objective outcomesLow riskNo blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding\
Blinding of outcome assessment ensured, and unlikely that the blinding could have been brokenHigh riskNo blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding\
Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blindingUnclear riskInsufficient information to permit judgment of low or high risk6.Blinding of outcome assessor (detection bias)\
Subjective outcomesLow riskBlinding of outcome assessment ensured, and unlikely that the blinding could have been brokenHigh riskNo blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding\
Blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blindingUnclear riskInsufficient information to permit judgment of low or high risk7. Incomplete outcome data (attrition bias)\
For all outcomes except retention in treatment or drop outLow riskNo missing outcome data\
Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias)\
Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups\
For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically‐relevant impact on the intervention effect estimate\
For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically‐relevant impact on observed effect size\
Missing data have been imputed using appropriate methods\
All randomised patients are reported/analysed in the group they were allocated to by randomisation irrespective of non‐compliance and co‐interventions (intention to treat)High riskReason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups\
For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate\
For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size\
\'As‐treated\' analysis done with substantial departure of the intervention received from that assigned at randomisationUnclear riskInsufficient information to permit judgment of low or high risk (e.g. number randomised not stated, no reasons for missing data provided; number of dropout not reported for each group)8 Selective reporting (reporting bias)Low riskThe study protocol is available and all of the study\'s pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way\
The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre‐specified (convincing text of this nature may be uncommon)High riskNot all of the study\'s pre‐specified primary outcomes have been reported\
One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified\
One or more reported primary outcomes were not pre‐specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);\
One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta‐analysis\
The study report fails to include results for a key outcome that would be expected to have been reported for such a studyUnclear riskInsufficient information to permit judgment of low or high risk

**DomainJudgmentDescriptionBias due to confoundingLow risk** (the study is comparable to a well‐performed randomised trial with regard to this domain)No confounding expected**Moderate risk** (the study is\
sound for a non‐randomised study with regard to this domain but cannot be considered comparable to a well performed randomised trial)Confounding expected, all known critically important confounding domains appropriately measured and adjusted for;\
and\
Reliability and validity of measurement of a critically important domains were sufficient that we do not expect serious residual confounding.**Serious risk** (the study has some important problems)At least one known critically important domain not appropriately measured, or not adjusted for;\
or\
Reliability or validity of measurement of a critically important domain was low enough that we expect serious residual confounding.**Critical risk** (the study is too problematic to provide any useful evidence on the effects of intervention)Confounding inherently not controllable, or use of negative controls strongly suggests unmeasured confounding**No information** on which to base a judgment about risk of bias for this domainNo information on whether confounding might be present**Bias in selection of participants into the studyLow risk**All participants who would have been eligible for the target trial were included in the study and start of follow‐up and start of intervention coincide for all participants**Moderate risk**Selection into the study may have been related to intervention and outcome, but the authors used appropriate methods to adjust for the selection bias;\
or\
Start of follow‐up and start of intervention do not coincide for all participants, but the proportion of participants for which this was the case was too low to induce important bias; the authors used appropriate methods to adjust for the selection bias; or the review authors are confident that the rate (hazard) ratio for the effect of intervention remains constant over time.**Serious risk**Selection into the study was related to intervention and outcome;\
or\
Start of follow‐up and start of intervention do not coincide, and a potentially important amount of follow‐up time is missing from analyses, and the rate ratio is not constant over time.**Critical risk**Selection into the study was strongly related to intervention and outcome;\
or\
A substantial amount of follow‐up time is likely to be missing from analyses, and the rate ratio is not constant over time.**No information**No information is reported about selection of participants into the study or whether start of follow‐up and start of intervention coincide**Bias in measurement of interventionsLow risk**Intervention status is well defined and based solely on information collected at the time of intervention**Moderate risk**Intervention status is well defined but some aspects of the assignments of intervention status were determined retrospectively**Serious risk**Intervention status is not well defined, or major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome**Critical risk**(Unusual) An extremely high amount of misclassification of intervention status, e.g. because of unusually strong recall biases**No information**No definition of intervention or no explanation of the source of information about intervention status**Bias due to departures from intended**\
**interventionsLow risk**No bias due to departure from the intended intervention is expected, for example if both the intervention and comparator are implemented over a short time period, and subsequent interventions are part of routine medical care, or if the specified comparison relates to initiation of intervention regardless of whether it is continued**Moderate risk**Bias due to departure from the intended intervention is expected, and switches, co‐interventions, and some problems with intervention fidelity are appropriately measured and adjusted for in the analyses. Alternatively, most (but not all) departures from intended intervention reflect the natural course of events after initiation of intervention.**Serious risk**Switches in treatment, co‐interventions, or problems with implementation fidelity are apparent and are not adjusted for in the analyses.**Critical risk**Substantial departures from the intended intervention are present and are not adjusted for in the analysis**.No information**No information is reported on whether there is departure from the intended intervention.**Bias due to missing dataLow risk**Data were reasonably complete;\
or\
Proportions and reasons of missing participants were similar across intervention groups;\
or\
Analyses that addressed missing data are likely to have removed any risk of bias.**Moderate risk**Proportions of missing participants differ across\
interventions or reasons for missingness differ minimally across interventions;\
and\
Missing data were not addressed in the analysis.**Serious risk**Proportions of missing participants differ substantially across interventions or reasons for missingness differ substantially across interventions;\
and\
Missing data were addressed inappropriately in the analysis;\
or\
The nature of the missing data means that the risk of\
bias cannot be removed through appropriate analysis.**Critical risk**(Unusual) There were critical differences between\
interventions in participants with missing data that were not, or could not, be addressed through appropriate analysis.**No information**No information is reported about missing data or the\
potential for data to be missing**Bias in measurement of outcomesLow risk**The methods of outcome assessment were comparable across intervention groups;\
and\
The outcome measure was unlikely to be influenced by knowledge of the intervention received by study participants (i.e. is objective) or the outcome assessors were unaware of the intervention received by study participants;\
and\
Any error in measuring the outcome is unrelated to\
intervention status.**Moderate risk**The methods of outcome assessment were comparable across intervention groups;\
and\
The outcome measure is only minimally influenced by knowledge of the intervention received by study\
participants;\
and\
Any error in measuring the outcome is only minimally related to intervention status.**Serious risk**The methods of outcome assessment were not comparable across intervention groups;\
or\
The outcome measure was subjective (i.e. likely to be\
influenced by knowledge of the intervention received by study participants) and was assessed by outcome assessors aware of the intervention received by study participants;\
or\
Error in measuring the outcome was related to intervention status.**Critical risk**The methods of outcome assessment were so different that they cannot reasonably be compared across intervention groups.**No information**No information is reported about the methods of outcome assessment.**Bias in selection of the reported resultLow risk**There is clear evidence (usually through examination of a pre‐registered protocol or statistical analysis plan) that all reported results correspond to all intended outcomes, analyses and sub‐cohorts.**Moderate risk**The outcome measurements and analyses are consistent with an a priori plan; or are clearly defined, and internally and externally consistent;\
and\
There is no indication of selection of the reported analysis from among multiple analyses;\
and\
There is no indication of selection of the cohort or subgroups for analysis and reporting on the basis of the results.**Serious risk**Outcome measurements or analyses are internally or\
externally inconsistent;\
or\
There is a high risk of selective reporting from among\
multiple analyses;\
or\
The cohort or subgroup is selected from a larger study for analysis and appears to be reported on the basis of the results.**Critical risk**There is evidence or strong suspicion of selective reporting of results, and the unreported results are likely to be substantially different from the reported results.**No information**There is too little information to make a judgment, for example if only an abstract is available for the study.**Overall judgment about risk of biasLow risk**The study is judged to be at low risk of bias for all domains.**Moderate risk**The study is judged to be at low or moderate risk of bias for all domains.**Serious risk**The study is judged to be at serious risk of bias in at least one domain, but not at critical risk of bias in any domain.**Critical risk**The study is judged to be at critical risk of bias in at least one domain.**No information**There is no clear indication that the study is at\
serious or critical risk of bias and there is a lack of information in one or more key domains of bias (a judgment is required for this).

Comparison 1Current OST versus no OSTOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence adjusted analyses by region](#CD012021-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Current OST versus no OST, Outcome 1 HCV incidence adjusted analyses by region.126361Risk Ratio (Random, 95% CI)0.50 \[0.40, 0.63\]1.1 North America52245Risk Ratio (Random, 95% CI)0.57 \[0.42, 0.76\]1.2 Europe53494Risk Ratio (Random, 95% CI)0.43 \[0.27, 0.68\]1.3 Australia2622Risk Ratio (Random, 95% CI)0.42 \[0.25, 0.72\][2 HCV incidence adjusted analysis by study design](#CD012021-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Current OST versus no OST, Outcome 2 HCV incidence adjusted analysis by study design.126361Risk Ratio (Random, 95% CI)0.50 \[0.40, 0.63\]2.1 Prospective cohort103467Risk Ratio (Random, 95% CI)0.51 \[0.40, 0.65\]2.2 Cross‐sectional surveys22894Risk Ratio (Random, 95% CI)0.46 \[0.23, 0.89\][3 HCV incidence unadjusted analyses by different modes of OST provision](#CD012021-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Current OST versus no OST, Outcome 3 HCV incidence unadjusted analyses by different modes of OST provision.9Risk Ratio (Random, 95% CI)Subtotals only3.1 Ever used OST3375Risk Ratio (Random, 95% CI)0.81 \[0.52, 1.27\]3.2 Interrupted OST use31157Risk Ratio (Random, 95% CI)0.80 \[0.57, 1.10\]3.3 Detoxification1552Risk Ratio (Random, 95% CI)1.45 \[0.79, 2.66\]3.4 High dose2453Risk Ratio (Random, 95% CI)0.52 \[0.29, 0.94\]3.5 Low dose2453Risk Ratio (Random, 95% CI)0.85 \[0.44, 1.65\]

Comparison 2Sensitivity analysis: OST versus no OST, adjusted analyses excluding unpublished datasetsOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence](#CD012021-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Sensitivity analysis: OST versus no OST, adjusted analyses excluding unpublished datasets, Outcome 1 HCV incidence.85235Risk Ratio (Random, 95% CI)0.42 \[0.31, 0.58\]

Comparison 3Sensitivity analysis: OST versus no OST, adjusted analyses excluding studies at critical risk of biasOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence](#CD012021-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Sensitivity analysis: OST versus no OST, adjusted analyses excluding studies at critical risk of bias, Outcome 1 HCV incidence.95782Risk Ratio (Random, 95% CI)0.51 \[0.40, 0.64\]

Comparison 4Sensitivity analysis: OST versus no OST, adjusted analyses excluding cross‐sectional studiesOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence](#CD012021-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Sensitivity analysis: OST versus no OST, adjusted analyses excluding cross‐sectional studies, Outcome 1 HCV incidence.103467Risk Ratio (Random, 95% CI)0.51 \[0.40, 0.65\]

Comparison 5OST versus no OST, unadjusted analysisOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence](#CD012021-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 OST versus no OST, unadjusted analysis, Outcome 1 HCV incidence.169499Risk Ratio (Random, 95% CI)0.57 \[0.45, 0.73\]

Comparison 6High NSP coverage versus no/low NSP coverageOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence adjusted analyses by region](#CD012021-fig-00601){ref-type="fig"}Analysis 6.1Comparison 6 High NSP coverage versus no/low NSP coverage, Outcome 1 HCV incidence adjusted analyses by region.53530Risk Ratio (Random, 95% CI)0.79 \[0.39, 1.61\]1.1 North America3627Risk Ratio (Random, 95% CI)1.25 \[0.63, 2.46\]1.2 Europe22903Risk Ratio (Random, 95% CI)0.24 \[0.09, 0.62\][2 HCV incidence adjusted analyses by study design](#CD012021-fig-00602){ref-type="fig"}Analysis 6.2Comparison 6 High NSP coverage versus no/low NSP coverage, Outcome 2 HCV incidence adjusted analyses by study design.53530Risk Ratio (Random, 95% CI)0.95 \[0.50, 1.82\]2.1 Prospective cohorts3627Risk Ratio (Random, 95% CI)1.44 \[1.01, 2.05\]2.2 Cross‐sectional surveys22903Risk Ratio (Random, 95% CI)0.24 \[0.09, 0.62\]

Comparison 7Sensitivity analysis: high NSP versus low/no NSP, excluding unpublished dataOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence](#CD012021-fig-00701){ref-type="fig"}Analysis 7.1Comparison 7 Sensitivity analysis: high NSP versus low/no NSP, excluding unpublished data, Outcome 1 HCV incidence.43245Risk Ratio (Random, 95% CI)0.77 \[0.28, 2.13\]

Comparison 8Sensitivity analysis: high NSP versus low/no NSP, excluding cross‐sectional surveysOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence](#CD012021-fig-00801){ref-type="fig"}Analysis 8.1Comparison 8 Sensitivity analysis: high NSP versus low/no NSP, excluding cross‐sectional surveys, Outcome 1 HCV incidence.3627Risk Ratio (Random, 95% CI)1.25 \[0.63, 2.46\]

Comparison 9High NSP coverage versus low/no coverage, unadjusted estimatesOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence](#CD012021-fig-00901){ref-type="fig"}Analysis 9.1Comparison 9 High NSP coverage versus low/no coverage, unadjusted estimates, Outcome 1 HCV incidence.76455Risk Ratio (Random, 95% CI)0.78 \[0.39, 1.55\]

Comparison 10Low NSP coverage versus no coverageOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence, adjusted analyses](#CD012021-fig-01001){ref-type="fig"}Analysis 10.1Comparison 10 Low NSP coverage versus no coverage, Outcome 1 HCV incidence, adjusted analyses.62765Risk Ratio (Random, 95% CI)1.43 \[0.82, 2.49\]

Comparison 11Low NSP coverage versus no NSP, unadjusted analysisOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence](#CD012021-fig-01101){ref-type="fig"}Analysis 11.1Comparison 11 Low NSP coverage versus no NSP, unadjusted analysis, Outcome 1 HCV incidence.93242Risk Ratio (Random, 95% CI)1.41 \[0.95, 2.09\]

Comparison 12Combined OST and high/low NSP versus no OST and low/no NSPOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 HCV incidence adjusted analyses](#CD012021-fig-01201){ref-type="fig"}Analysis 12.1Comparison 12 Combined OST and high/low NSP versus no OST and low/no NSP, Outcome 1 HCV incidence adjusted analyses.36197Risk Ratio (Random, 95% CI)0.45 \[0.22, 0.94\]1.1 High NSP coverage33241Risk Ratio (Random, 95% CI)0.26 \[0.07, 0.89\]1.2 Low NSP coverage22956Risk Ratio (Random, 95% CI)0.87 \[0.44, 1.68\][2 HCV incidence unadjusted analyses](#CD012021-fig-01202){ref-type="fig"}Analysis 12.2Comparison 12 Combined OST and high/low NSP versus no OST and low/no NSP, Outcome 2 HCV incidence unadjusted analyses.46427Risk Ratio (Random, 95% CI)0.47 \[0.27, 0.80\]2.1 Combined OST and high NSP versus no OST and low/no NSP43356Risk Ratio (Random, 95% CI)0.29 \[0.13, 0.65\]2.2 Combined OST and low NSP versus no OST and low/no NSP33071Risk Ratio (Random, 95% CI)0.76 \[0.44, 1.33\]

Protocol first published: Issue 1, 2016 Review first published: Issue 9, 2017

**DateEventDescription**20 January 2016AmendedExternal source of support added

We have added a final review author, Prof Julie Bruneau, who contributed some of the unpublished data and advised on the review analyses and write‐up.

We have changed the title to refer to opioids instead of opiates. Opioid encompasses synthetic opiates as well as those derived from opium, whereas opiates just include drugs derived from opium.

We added in another control intervention that included low coverage of NSP. This became necessary as it was clear following data extraction that many comparisons were made against this intervention exposure.

We also added to the description of the \'Risk of bias\' assessment following its application. When the protocol was first published the tool was being piloted, and it was updated during the course of the review. We adapted our protocol to reflect these changes. We also added in additional confounders to be extracted from the protocol, since after extracting the first few papers it became clear that we had omitted relevant confounders.

We updated our approach to dealing with measures of treatment effect to reflect the dominant effect estimates that we were extracting. We treated odds ratios as an approximation of the risk ratio despite the variation in HCV incidence. We checked the legitimacy of this approach in a sensitivity analysis, excluding studies reporting odds ratios only.

We excluded studies where data regarding drug treatment or NSP were missing or unavailable from the analysis but not the review. We updated the review to clarify this point.

The subgroup analysis differed from that specified in the review protocol since there was insufficient information to assess impact by type of NSP, frequency of injecting, dose of OST, duration or age, ethnicity of participants. We did not assess impact by recruitment site of participants either since most studies recruited across multiple sites and methods, making it difficult to clearly differentiate methods.

The sensitivity analysis differed from that specified in the protocol in several ways. We did not exclude studies that reported incident rate ratios as effect estimates, since only a few studies used incident rate ratios. Instead we removed estimates derived from unpublished datasets as part of our sensitivity analyses since more estimates were derived in this way, making them a more substantive part of the analysis. The original protocol also stated that we would exclude studies that only assessed the impact of the intervention at baseline. We did this in the review but changed the wording to say that we excluded studies that used odds ratios as effect estimates and were cross‐sectional in design. This is the same as excluding baseline measures only, but we wanted to more clearly specify that the sensitivity analysis had explored the effect of pooling different study designs.

Characteristics of included studies \[ordered by study ID\] {#CD012021-sec2-0022}
===========================================================

[@CD012021-bbs2-0001]MethodsProspective cohort study; recruitment was done via RDS, street outreach and snowball samplingParticipantsCountry: Australia\
449 PWID, defined as \'regularly\' injecting illicit drugs in the last 6 months. Median age was 29.4 years, and 50% of participants reported injecting daily, but there was no information on the main drug being injected.InterventionsThe intervention in this study was use of opioid substitution therapy (OST); OST was defined as use of OST in the previous month. The comparison group was no current OST use.\
Follow‐up: 196 person years\
Study duration: 5 yearsOutcomesHCV seroconversion as measured by HCV antibody in serumNotesFunding source is the Australian National Health and Medical Research Council[@CD012021-bbs2-0002]MethodsProspective cohort study; recruitment was done via street outreach, and snowball samplingParticipantsCountry: Canada\
285 PWIDInterventionsThe interventions included in this study were needle syringe exchange programme (NSP) use in the previous 3 or 6 months, use of methadone maintenance in the previous 6 months. Further detail on the intensity of engagement with the intervention was gathered; researchers examined NSP use where 100% of needles/syringes used were obtained by NSP and a methadone dose of 0‐60 mg or 60+ mg, respectively. Comparisons were no NSP use in the previous 3 or 6 months or low NSP coverage (\< 100%), no OST use in the previous 6 months, or \< 59 mg of methadone\
Follow‐up: 589.3 person years\
Study duration: 7 yearsOutcomesHCV seroconversionNotesThe funding source was the Canadian Institutes of Health Research, US National Institute on Drug Abuse and the Réseau SIDA et Maladies Infectieuses du Fonds de la Recherche en Sante du Quebec[@CD012021-bbs2-0003]MethodsProspective cohort studyParticipantsCountry: Wales, UK\
700 PWID, defined as injecting drugs in the previous 4 weeks. 29% were female and the mean age was 27.2 years. The main drug injected was not reported, but 42% had injected stimulants.InterventionsThe intervention was either in opioid substitution treatment or not\
Follow‐up: 287.3 person years\
Study duration: 2 yearsOutcomesHCV seroconversionNotesFunded by the Welsh Assembly Government[@CD012021-bbs2-0004]MethodsRetrospective cohort studyParticipantsCountry: Australia\
1741 PWID; the mean age was 29.2 years and 42% were female; main drug was not reportedInterventionsThe intervention was defined as either continuous or interrupted methadone maintenance treatment; the comparison was no methadone maintenance\
Follow‐up: 85.4 person years\
Study duration: 4 yearsOutcomesHCV seroconversionNotesIndividual funding was received from Research Fund of the Macfarlane Burnet Centre, Victorian Department of Health and Community Services Public Health Training Programme, the Commonwealth Department of Health and Family Service.[@CD012021-bbs2-0005]MethodsCase‐control studyParticipantsCountry: USA\
46 PWID, where PWID status was defined as having injected drugs in the previous 6 months (cases). 24% of the sample were \< 25 years, 45% were female; the main drug injected was not reportedInterventionsThe intervention under study was ever having used a needle syringe exchange programme and comparison was never having used a NSP\
Follow‐up: n/a\
Study duration: 2 yearsOutcomesHCV seroconversion defined by presence of HCV antibodiesNotesFunded by the American Foundation for AIDS Research[@CD012021-bbs2-0006]MethodsProspective cohort studyParticipantsCountry: USA\
2462 PWID, defined as having injected drugs in the previous 12 months. 19% were \< 25 years, 38% were female, 54% injected heroin and 59% injected dailyInterventionsThe intervention under study was either current sporadic or current regular needle syringe exchange programme use; the comparison was no use of the NSP.\
Follow‐up: 209 person years\
Study duration: 2 yearsOutcomesHCV seroconversion defined by presence of HCV antibodies (the timeframe for seroconversion was within the previous 12 months)NotesFunded by the National Institute on Drug Abuse and Centre for Disease Control[@CD012021-bbs2-0007]MethodsProspective cohort study; recruitment was done via RDS and street outreachParticipantsCountry: USA\
4663 PWID, defined as injecting drugs in the previous 6 or 12 months. 28% were less than 21 years old, 38% were female; main drug injected was not reported, but 49% injected dailyInterventionsThe intervention was participation (yes/no) in a needle syringe exchange programme (NSP) in either the previous 3 months or 6 months\
Follow‐up: n/a\
Study duration: 10 yearsOutcomesHCV seroconversion measured by the presence of HCV antibodiesNotesFunding source not specified[@CD012021-bbs2-0008]MethodsCross‐sectional study. Recruitment of study participants was done via RDSParticipantsCountry: England, UK\
299 PWID, defined as having injected drugs in the previous 4 weeks. 17% were \< 25 years old, 23% were female, 94% injected opiates, 40% injected dailyInterventionsThe interventions were as follows:\
Low NSP coverage and not on OSTLow NSP coverage and OSTHigh NSP coverage and no OSTHigh NSP coverage and OST\
Comparisons were no current use of OST, no or low NSP coverage\
Follow‐up: n/a\
Study duration: 6 monthsOutcomesHCV seroconversion defined as HCV RNA positive and HCV antibody negative (dried blood spot testing); the window period for the outcome was 51--75 days (range)NotesFunded by the National Treatment Agency for Substance Use and Health Protection Agency[@CD012021-bbs2-0009]MethodsCross‐sectional study; recruitment of study participants was done via RDSParticipantsCountry: England, UK\
948PWID, defined as having injected drugs in the previous 4 weeks. Median age was 33 years, 48% injected heroin as their main drug, but 64% had injected crack/cocaine in the previous month, 19% were female and 53% injected dailyInterventionsThe interventions were as follows:\
Low NSP coverage and not on opioid substitution treatment OSTLow NSP coverage and OSTHigh NSP coverage and no OSTHigh NSP coverage and OST\
Comparisons were no current use of OST, no or low NSP coverage\
Follow‐up: 6 monthsOutcomesHCV seroconversion defined as HCV RNA positive and HCV antibody negative (dried blood spot testing); the window period for the outcome was 51--75 days (range)\
Follow‐up: n/a\
Study duration: 6 monthsNotesFunded by National Treatment Agency for Substance Use and the Health Protection Agency[@CD012021-bbs2-0010]MethodsProspective cohort study; recruitment was conducted via privileged access interviews and snowball samplingParticipantsCountry: England, UK\
272 PWID, defined as having injected drugs in the previous 4 weeks. Median age was 27.6 years, 29% were female, 35% mainly injecting heroin, 84% injected dailyInterventionsThe intervention of interest was use of methadone maintenance treatment in the previous 6 months or longer, compared to no methadone in the same time period\
Follow‐up:116.7 person years\
Study duration: 2 yearsOutcomesHCV seroconversionNotesFunded by the UK Department of Health[@CD012021-bbs2-0011]MethodsProspective cohort study; recuitment was conducted at drug treatment centresParticipantsCountry: France\
321 PWID, defined as ever having injected drugs. Median age was 26.9 years, 17.6% were female, 28% injected opiates, 84% injected dailyInterventionsThe intervention under study was having received OST in the 3 months prior to study enrollment; the comparison was no OST in the 3 months prior to study enrollment\
Follow‐up: 178.4 person years\
Study duration: 1 yearOutcomesSeroconversion measured as the presence of HCV antibodies in oral fluid and serum on positive tests; the window period for the outcome was the midpoint between previous negative oral fluid test and first positive serum testNotesFunded by the Agence Nationale de Recherche su le SIDA, Institute de Veille Sanitaire, Programme Hospitalier de Recherce Clinique, Direction Departementale de l\'Action Sanitaire et Sociale du Nord, Academie Nationale de Medecine[@CD012021-bbs2-0012]MethodsProspective cohort study; recruitment was conducted in community settings and in low‐threshold drug treatment settingsParticipantsCountry: Australia\
294 PWID, defined as injection in the previous 6 months. Median age was 24 years, 32% were female, 69% injected heroinInterventionsThe intervention under study was having received OST in the previous 6 months; the comparison was no OST in the previous 6 months\
Follow‐up: 212.86 person years\
Study duration: 3 yearsOutcomesSeroconversion as measured by anti‐HCV serology at baseline using 1‐2 third‐generation enzyme‐linked immunosorbent assays. PCR testing to detect HCV RNA on all final HCV antibody negative specimensNotesFunded by the Australian National Health and Medical Research Council[@CD012021-bbs2-0013]MethodsProspective cohort study; recruitment was conducted through community‐based outreachParticipantsCountry: USA\
471 PWID, defined as having injected within the preceding 11 years. Median age was 34 years, 18.3% were female, 65% injected heroin and cocaine, 92% had injected in the previous year at baselineInterventionsThe intervention under study was being in methadone treatment in the previous 6 months; the comparison was no methadone treatment in the previous 6 months\
Follow‐up: 166.5 person years\
Study duration: 20 yearsOutcomesHCV seroconversion, measured through serum samplesNotesFunded by the National Institute on Drug Abuse[@CD012021-bbs2-0014]MethodsProspective cohort study; recruitment included snowball samplingParticipantsCountry: Canada\
3741 PWID, defined as having injected drugs in the previous 4 weeks. 30% were female, 34% injected opiates and the mean age was 34 years among methadone users and 23 years among non‐methadone usersInterventionsThe interventions under study were:\
Active participation in methadone maintenance treatment (MMT) in last 6 monthsMMT once during follow‐up,MMT \> 2 times during follow‐up\
Comparison was no use of MMT within the same time periods\
Follow‐up: 2108.4 person years\
Study duration: 16 yearsOutcomesHCV seroconversion defined by presence of HCV antibodiesNotesFunded by the US National Institutes on Drug Abuse[@CD012021-bbs2-0015]MethodsProspective cohort study; recruitment occurred through street outreachParticipantsCountry: USA\
552 PWID, defined as people who have injected drugs in the previous month and less than 30 years old. 42.5% were \< 22 years, 22% were female and 61% injected heroin/heroin mixed in the previous monthInterventionsThe intervention under study was use of a NSP in the previous 3 months and the comparison was no use of NSP\
Follow‐up: 681.3 person years\
Study duration: 15 yearsOutcomesHCV seroconversion defined by presence of HCV antibodies or HCV RNANotesFunded by the National Institute on Drug Abuse[@CD012021-bbs2-0016]MethodsCross‐sectional study; participants were recruited at NSPsParticipantsCountry: Scotland, UK\
7954 PWID, defined as ever having injected drugs (but 80% had injected in previous 6 months). Mean age is 34 years, 27.5% are female, 55.3% inject daily and 17% injected stimulantsInterventionsThe interventions were defined as:\
Needle syringe exchange (NSP) coverage: low vs highParaphernalia coverage: low vs highOpioid substitution treatment (OST): current vs not currentNSP and OST combined: low NSP, no OST vs low NSP with OST, high NSP no OST, high NSP OST, did not inject OSTNSP, paraphernalia, and OST combined: low NSP, low para, no OST vs low NSP, low para with OST, high NSP, low para, no OST, high NSP, low para, OST, high NSP, high para, no OST, high NSP, high para, OST, did not inject OST\
The comparisons were no OST or no/low NSP use\
Follow‐up: 602.7 person years\
Study duration: 4 yearsOutcomesThe outcome was HCV seroconversion defined as being HCV antibody negative and HCV RNA positiveNotesFunded by the Scottish Government[@CD012021-bbs2-0017]MethodsProspective cohort study; recruitment included snowball samplingParticipantsCountry: Canada\
1345 PWID, defined as having injected drugs in the previous 4 weeks. 30% were female, the median age was 34 years, 63% injected opiates and 54% injected stimulants, 54% injected dailyInterventionsThe intervention under study was\
Attendance at least once per week at NSP in previous 6 months (yes or no)Methadone maintenance treatment in previous 6 months (yes or no)\
The comparison was NSP attendance or no methadone in the previous 6 months\
Follow‐up: 207.9 person years\
Study duration: 3 yearsOutcomesHCV seroconversion measured by HCV antibody positivityNotesFunding source was not specified[@CD012021-bbs2-0018]MethodsCase‐control study; recruitment methods employed a convenience sample of service attendersParticipantsCountry: Italy\
746 PWID, defined as being a heroin user. 21% were \< 28 years, 3% were female, 100% injected opiates and 32% also injected stimulants, 69% injected dailyInterventionsThe intervention under study was being in methadone maintenance treatment in the previous 6 months, the comparison was no methadone maintenance in the same time period\
Follow‐up: 73.4 person years\
Study duration: 2 yearsOutcomesHCV seroconversion, measured by HCV antibody positivity in serum samplesNotesFunded by the Progretto AIDS, Ministero della Sanita‐Instituto Superiore di Sanita[@CD012021-bbs2-0019]MethodsSerial cross‐sectional survey; recruitment methods employed service attenders at drug treatment programmesParticipantsCountry: Canada\
1380 PWID, defined as having injected in the previous 6 months. Mean age was 31.8 years, 27% were female, 19% injected opiates and 75% injected stimulantsInterventionsThe intervention under study was using an NSP in the previous 6 months, and the comparison was no use of the NSP\
Follow‐up: 267 person years\
Study duration: 6 yearsOutcomesHCV RNA positive on anti‐HCV negative (oral fluid). HCV seroconversions were attributed to the midpoint between the previous negative and first positive test resultsNotesFunded by the Health Canada, Ministere de la Sante et des Services Sociaux du Quebec[@CD012021-bbs2-0020]MethodsProspective cohort study; recruitment occurred via community outreach and snowball samplingParticipantsCountry: China\
379 PWID, defined as having injected drugs in the previous 3 months. 44% were \< 28 years and 100% injected opiates. There was no information on sex or frequency of injecting.InterventionsThe intervention of interest was lifetime experience of methadone maintenance treatment (yes or no).\
Follow‐up: 258 person years\
Study duration: 3 yearsOutcomesHCV antibody positivity in serum samples (incidence density); the time of seroconversion was the midpoint between the previous negative and first positive HCV antibody test resultNotesFunded by the Ministry of Science and Technology of China, the National Natural Science Foundation of China, China Comprehensive Integrated Programmes for Research on AIDS, the National Institute of Allergy and Infectious Diseases and the National Institutes of Health[@CD012021-bbs2-0021]MethodsProspective cohort study; recruitment via community outreach and snowball samplingParticipantsCountry: Canada\
377 PWID, defined as having injected in the previous 4 weeks. Median age was 23 years, 53% were female, 18% injected opiates, 10% injected stimulants, 18% injected dailyInterventionsThe intervention of interest was being in methadone maintenance treatment (yes or no) at the time of survey; comparison was no current use of methadone maintenance\
Follow‐up:338.6 person years\
Study duration: 6 yearsOutcomesHCV antibody positivity in serum samples (incidence density); the time of seroconversion was the midpoint between the previous negative and first positive HCV antibody test resultNotesFunded by the Institute for Aboriginal Peoples Health and the Canadian Institutes for Health Research[@CD012021-bbs2-0022]MethodsProspective cohort study; recruitment from a drug treatment settingParticipantsCountry: USA\
716 PWID, defined as having injected drugs in the previous 4 weeks. 5.4% were \< 25 years, 49% were female, 23% injected stimulants and 25% injected dailyInterventionsThe interventions under study were:\
Left methadone maintenance treatment (MMT) at least once during follow‐up but were re‐enrolled at their follow‐up visitRemained in MMT throughout the follow‐up period\
The comparison was no MMT.\
Follow‐up: 80 person years\
Study duration: 4 yearsOutcomesHCV seroconversion, as demonstrated by the presence of HCV antibodies in serumNotesFunded by the Centers for Disease Control and Prevention[@CD012021-bbs2-0023]MethodsProspective cohort study; recruitment via street outreach, targeted advertising, and peer referralsParticipantsCountry: USA\
702 PWID, defined as having injected in the previous 6 months. 53% were aged 18‐22 years, 49% were female, 23% injected stimulants and 39% injected dailyInterventionsThe intervention of interest was use of an NSP in the previous 6 months and the comparison was no use of the NSP\
Follow‐up: 327.2 person years\
Study duration: 2 yearsOutcomesHCV seroconversion as demonstrated by the presence of HCV antibodies in serum; time of seroconversion was taken to be the midpoint between the previous negative and first positive HCV antibody test resultNotesFunding source was not specified[@CD012021-bbs2-0024]MethodsProspective cohort study; recruitment via street outreachParticipantsCountry: USA\
992 PWID, defined as having injected in the previous 4 weeks and aged \< 30 years. 16% were aged 15‐18 years, 32% were female, 60% injected opiates and 33.2% injected stimulantsInterventionsThe interventions of interest included:\
Opiate agonist detoxification in previous 3 monthsOpiate agonist therapy maintenance treatment in previous 3 months. Recent opioid agonist therapy included treatment with buprenorphine or methadone anytime within the past year at the baseline screening interview, within the past 3 months at quarterly interviews for participants in waves 1 and 3, and within the past week for participants in wave 2\
The comparison was no opiate agonist therapy in the same time frame\
Follow‐up: 680 person years\
Study duration: 13 yearsOutcomesHCV seroconversion. Incidence was calculated using behavior or characteristic at the previous period that participant was seronegative for HCV (uninfected during follow‐up) or the first HCV‐seropositive risk period (incident infections). Incident acute HCV infections were: a new test result positive for HCV RNA and/or anti‐HCV after a previously documented test result negative for anti‐HCV; or a positive HCV RNA test result concomitant with a negative anti‐HCV test result.NotesFunded by the National Institute on Drug Abuse, National Institute of Health, National Institute on Alcohol and Alcoholism[@CD012021-bbs2-0025]MethodsProspective cohort study; recruitment was street‐based and employed targeted sampling and chain‐referral methodsParticipantsCountry: Spain\
513 PWID; PWID were required to have used heroin at least 12 days and at least 1 day in the past 3 months. 40% were \< 25 years, 27% were female, 31% injected stimulants. There was no information on daily injecting.InterventionsThe intervention of interest was methadone maintenance; further details of the intervention (e.g. intensity or duration of engagement in the intervention) was not specified, the comparison was no use of methadone maintenance.\
Follow‐up: 105.4 peron years\
Study duration: 3 yearsOutcomesHCV seroconversion, defined by HCV antibody positivity by dried blood spot testingNotesFunded by the Foundation for AIDS Prevention and Research[@CD012021-bbs2-0026]MethodsRetrospective cohort study; recruitment at drug treatment servicesParticipantsCountry: Australia\
1078 PWID, 61.5% were \< 20 years, 55.9% were female, 19% injected opiates, 27.9% injected stimulantsInterventionsThe intervention under study was ever having received methadone; the comparison was no methadone\
Follow‐up:148.2 person years\
Study duration: 2 yearsOutcomesHCV seroconversionNotesFunded by the Australian National Council on AIDS and Related Diseases[@CD012021-bbs2-0027]MethodsProspective cohort study; enrollment occurred through \'open\' recruitmentParticipantsCountry: Netherlands\
168 PWID, defined as those who had ever injected drugs. Median age was 31.4 years, 33% were female, 33% injected opiates and 51% injected stimulants, 51.7% injected dailyInterventionsThe interventions of interest were measured as follows:\
Incomplete harm reduction: any dose of methadone daily, injection in previous 6 months, irregular or no use of NSP; OR 0‐59 mg of methadone daily in past 6 months, always use NSPFull harm reduction: ≥ 60 mg of methadone daily in past 6 months; no injecting drug use; ≥ 60 mg methadone daily, injecting drug use in past 6 months, always use NSPLimited dependence on harm reduction: 1‐59 mg of methadone in past 6 months, no injecting drug useNo dependence on harm reduction: no methadone in in past 6 months, no injection in past 6 months.\
The comparsion was no methadone in the past 6 months, and/or no use of NSP or no injection\
Follow‐up: 598.56 person years\
Study duration: 22 yearsOutcomesHCV seroconversionNotesFunded by the Netherlands National Institute for Public Health and the Environment[@CD012021-bbs2-0028]MethodsProspective cohort study; recruitment via snowball sampling, social networks, RDS, and targeted outreach samplingParticipantsCountry: Australia\
166 PWID, defined as those who had injected drugs in the previous 12 months. Median age was 27 years, 25% were female. Participants mainly injecting opioids, but frequency of injecting was not reportedInterventionsThe intervention assessed was having accessed a needle syringe exchange programme or opioid substitution treatment in the previous 6 months, the comparison was no use of the NSP or OST in the same time frame.\
Follow‐up: 215.2 person years.\
Study duration: 3 yearsOutcomesHCV seroconversion defined as being negative for HCV antibodies and positive for HCV RNANotesFunded by the National Health and Medical Research Council[^7]

Characteristics of excluded studies \[ordered by study ID\] {#CD012021-sec2-0023}
===========================================================

StudyReason for exclusion[@CD012021-bbs2-0029]No outcome of interest[@CD012021-bbs2-0030]No outcome of interest[@CD012021-bbs2-0031]No intervention of interest: no OST or NSP[@CD012021-bbs2-0032]No outcome of interest[@CD012021-bbs2-0033]No outcome of interest; no comparison of interest: all participants on OST[@CD012021-bbs2-0034]No outcome of interest[@CD012021-bbs2-0035]No outcome of interest[@CD012021-bbs2-0036]No intervention of interest: no OST or NSP[@CD012021-bbs2-0039]No outcome of interest; simulation study[@CD012021-bbs2-0037]No outcome of interest[@CD012021-bbs2-0038]No outcome of interest[@CD012021-bbs2-0040]No outcome of interest[@CD012021-bbs2-0041]No outcome of interest[@CD012021-bbs2-0042]No outcome of interest. No comparison of interest: all participants on OST[@CD012021-bbs2-0043]No outcome of interest[@CD012021-bbs2-0044]No outcome of interest[@CD012021-bbs2-0045]No comparison of interest: all participants on OST[@CD012021-bbs2-0046]No outcome of interest[@CD012021-bbs2-0047]No intervention of interest: no OST or NSP[@CD012021-bbs2-0048]No outcome of interest; no intervention of interest: no OST or NSP[@CD012021-bbs2-0049]No outcome of interest[@CD012021-bbs2-0050]No outcome of interest; no intervention of interest: no OST or NSP[@CD012021-bbs2-0051]No outcome of interest; no intervention of interest: no OST or NSP[@CD012021-bbs2-0052]No intervention of interest: no OST or NSP[@CD012021-bbs2-0053]No outcome of interest[@CD012021-bbs2-0054]No outcome of interest[@CD012021-bbs2-0055]No outcome of interest[@CD012021-bbs2-0056]No outcome of interest[@CD012021-bbs2-0057]Editorial[@CD012021-bbs2-0058]No intervention of interest: no OST or NSP[@CD012021-bbs2-0059]No outcome of interest; No intervention of interest: no OST or NSP[@CD012021-bbs2-0060]No outcome of interest; no intervention of interest: no OST or NSP[@CD012021-bbs2-0061]No outcome of interest[@CD012021-bbs2-0062]No outcome of interest[@CD012021-bbs2-0063]No comparison of interest: all participants on OST[@CD012021-bbs2-0064]No outcome of interest; simulation study[@CD012021-bbs2-0065]No intervention of interest: no OST or NSP[@CD012021-bbs2-0066]No outcome of interest; simulation study[@CD012021-bbs2-0067]No intervention of interest: no OST or NSP[@CD012021-bbs2-0068]No comparison of interest[@CD012021-bbs2-0069]No outcome of interest[@CD012021-bbs2-0070]No intervention of interest: no OST or NSP[@CD012021-bbs2-0071]No outcome of interest[@CD012021-bbs2-0072]No outcome of interest[@CD012021-bbs2-0073]No outcome of interest[@CD012021-bbs2-0074]No intervention of interest: no OST or NSP[@CD012021-bbs2-0075]No intervention of interest: no OST or NSP[@CD012021-bbs2-0076]No intervention of interest: no OST or NSP[@CD012021-bbs2-0077]No intervention of interest: no OST or NSP[@CD012021-bbs2-0078]Overview[@CD012021-bbs2-0079]No intervention of interest: no OST or NSP[@CD012021-bbs2-0080]No comparison of interest: all on OST[@CD012021-bbs2-0081]No outcome of interest; simulation model[@CD012021-bbs2-0082]No outcome of interest[@CD012021-bbs2-0083]No intervention of interest: no OST or NSP[@CD012021-bbs2-0084]No outcome of interest[@CD012021-bbs2-0085]No outcome of interest. No comparison of interest: all participants on OST[@CD012021-bbs2-0086]No outcome of interest[@CD012021-bbs2-0087]No intervention of interest: no OST or NSP[@CD012021-bbs2-0088]No intervention of interest: no OST or NSP[@CD012021-bbs2-0089]No intervention of interest: no OST or NSP[@CD012021-bbs2-0090]No outcome of interest[@CD012021-bbs2-0091]No outcome of interest[@CD012021-bbs2-0092]No outcome of interest[@CD012021-bbs2-0093]No comparison of interest: all participants on OST[@CD012021-bbs2-0094]No intervention of interest: no OST or NSP[@CD012021-bbs2-0095]No intervention of interest: no OST or NSP[@CD012021-bbs2-0096]No comparison of interest: all participants on OST[@CD012021-bbs2-0097]No intervention of interest: no OST or NSP[@CD012021-bbs2-0098]No intervention of interest: no OST or NSP[@CD012021-bbs2-0099]No intervention of interest: no OST or NSP[@CD012021-bbs2-0100]No intervention of interest: no OST or NSP[@CD012021-bbs2-0101]No outcome of interest. No intervention of interest: no OST or NSP[@CD012021-bbs2-0102]No intervention of interest: no OST or NSP[@CD012021-bbs2-0103]No outcome of interest[@CD012021-bbs2-0104]No outcome of interest. No comparison of interest: all participants on OST[@CD012021-bbs2-0105]No outcome of interest[@CD012021-bbs2-0106]No outcome of interest. No intervention of interest: no OST or NSP[@CD012021-bbs2-0107]No outcome of interest. No intervention of interest: no OST or NSP[@CD012021-bbs2-0108]No intervention of interest (NSP shuts down for some of the follow‐up)[@CD012021-bbs2-0109]No intervention of interest: no OST or NSP[@CD012021-bbs2-0110]No intervention of interest: no OST or NSP[@CD012021-bbs2-0111]No intervention of interest: no OST or NSP[@CD012021-bbs2-0112]No outcome of interest. No intervention of interest: no OST or NSP[@CD012021-bbs2-0113]No intervention of interest: no OST or NSP[@CD012021-bbs2-0114]No outcome of interest[@CD012021-bbs2-0115]No outcome of interest. No intervention of interest: no OST or NSP[@CD012021-bbs2-0116]No outcome of interest. No intervention of interest: no OST or NSP[@CD012021-bbs2-0117]No outcome of interest[@CD012021-bbs2-0118]No intervention of interest: no OST or NSP[@CD012021-bbs2-0119]No intervention of interest: doesn\'t specify OST, only that it is drug treatment[@CD012021-bbs2-0120]No comparison of interest: all participants on OST[@CD012021-bbs2-0121]No intervention of interest: no OST or NSP[@CD012021-bbs2-0122]No outcome of interest[@CD012021-bbs2-0123]No outcome of interest[@CD012021-bbs2-0124]No outcome of interest[@CD012021-bbs2-0125]No outcome of interest[@CD012021-bbs2-0126]No outcome of interest[@CD012021-bbs2-0127]No comparison of interest: all participants on OST[@CD012021-bbs2-0128]No comparison of interest: all participants on OST[@CD012021-bbs2-0129]No outcome of interest[^8]

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD012021-sec2-0024}
======================================================================

[@CD012021-bbs2-0130]MethodsProspective cohortParticipants313 HCV‐seronegative PWID (injection in the previous month) were enrolled with at least one follow‐up visit. 22% were female, 43% were under 30 years old and 58% injected cocaineInterventionsOpioid agonist therapy (1‐59 mg, methadone or suboxone, ≥ 60 mg methadone) and injection material coverage (100% safe sources vs no)OutcomesSeroconversion to HCV antibody positiveNotesThe study was conducted in Montreal, Canada. No funding source is specified.[@CD012021-bbs2-0131]Methods---Participants---Interventions---Outcomes---NotesThere is no abstract, and the text is in Chinese.[@CD012021-bbs2-0132]Methods---Participants---Interventions---Outcomes---NotesThere is no abstract, and the text is in Chinese.[@CD012021-bbs2-0133]Methods---Participants---Interventions---Outcomes---NotesThere is no abstract, and the text is in Chinese.[@CD012021-bbs2-0134]Methods---Participants---Interventions---Outcomes---NotesThere is no abstract, and the text is in Chinese.[@CD012021-bbs2-0135]Methods---Participants---Interventions---Outcomes---NotesThe text is in French, and there is little information in the abstract.[@CD012021-bbs2-0136]MethodsProspective cohort recruited between 2011 and 2015ParticipantsPeople who inject drugs, defined as regular injectors (at least one a month in the 6 months prior to recruitment), a total of 502 participants, approximately 36% were female and mean age 30 was yearsInterventionsCurrent opoid substitution therapy prescription; NSP as usual source of syringe acquisition in the past month, measure of injections covered by sterile syringe (syringes acquired divided by syringes distributed divided by past week injecting frequency)OutcomesHCV RNA positive among negative samplesNotesData drawn from the Melbourne injecting drug use cohort study (MIX). Funding provided by the Colonial Foundation Trust and the National Reserch Council[@CD012021-bbs2-0137]MethodsLongitudinal incidence study, participants recruited in community settings through peer referrals in places where drugs are usedParticipantsPeople who inject drugs defined as injection at least once in the previous 3 months and residing in Delhi. A total of 2292 PWID recruited of whom all were male; median age was 29 yearsInterventionsAccessed NSP in the previous 3 monthsOutcomesanti HCV negative and HCV RNA positiveNotesFunding received from the Canadian Government (Department of Foreign Affairs, Trade and Development Canada). No incidence data reported, but need to contact authors for measures[@CD012021-bbs2-0138]Methods---Participants---Interventions---Outcomes---NotesThere is no abstract, and the text is in German.[@CD012021-bbs2-0139]Methods---Participants---Interventions---Outcomes---NotesThere is no abstract, and the text is in Japanese.[^9]
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[^1]: Editorial Group: Cochrane Drugs and Alcohol Group.

[^2]: ^a^Downgraded one level due to overall moderate risk of bias in 2 studies, overall serious risk of bias in 6 studies, 2 studies at overall critical risk of bias in 2 studies; not enough information to make judgment in 2 studies. ^b^Upgraded one level due to large magnitude of the effect: RR: 0.5.

[^3]: ^a^Downgraded one level due to serious overall risk of bias in all the studies. ^b^Downgraded one level due to significant heterogeneity: I^2^: 77%.

[^4]: ^a^Downgraded one level due to serious overall risk of bias in all studies. ^b^Upgraded one level due to very large magnitude of the effect: RR: 0.26.

[^5]: **CI**: confidence interval; **HCV**: hepatitis C virus; **OST**: opioid substitution therapy.

[^6]: **CI**: confidence interval; **HCV**: hepatitis C virus; **NSP**: needle syringe programmes.

[^7]: **HCV**: hepatitis C virus; **NSP**: needle syringe programme; **OST**: opioid substitution therapy; **PCR**: polymerase chain reaction; **PWID**: people who inject drugs; **RDS**: respondent‐driven sampling.

[^8]: NSP: needle syringe programme; OST: opioid substitution therapy.

[^9]: **HCV**: hepatitis C virus; **NSP**: needle syringe programme; **PWID**: people who inject drugs.
